CA2622573A1 - Ophthalmic syringe - Google Patents
Ophthalmic syringe Download PDFInfo
- Publication number
- CA2622573A1 CA2622573A1 CA002622573A CA2622573A CA2622573A1 CA 2622573 A1 CA2622573 A1 CA 2622573A1 CA 002622573 A CA002622573 A CA 002622573A CA 2622573 A CA2622573 A CA 2622573A CA 2622573 A1 CA2622573 A1 CA 2622573A1
- Authority
- CA
- Canada
- Prior art keywords
- needle
- barrel
- injection solution
- syringe
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003814 drug Substances 0.000 claims abstract description 43
- 238000002347 injection Methods 0.000 claims description 110
- 239000007924 injection Substances 0.000 claims description 110
- 239000000243 solution Substances 0.000 claims description 58
- 230000035515 penetration Effects 0.000 claims description 33
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical group COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 claims description 31
- 229940124597 therapeutic agent Drugs 0.000 claims description 26
- -1 chlorobutyl Chemical group 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 22
- 229940005014 pegaptanib sodium Drugs 0.000 claims description 21
- 239000002245 particle Substances 0.000 claims description 19
- 239000002699 waste material Substances 0.000 claims description 17
- 238000009472 formulation Methods 0.000 claims description 16
- 108091023037 Aptamer Proteins 0.000 claims description 12
- 229920001971 elastomer Polymers 0.000 claims description 9
- 238000007789 sealing Methods 0.000 claims description 8
- 238000000576 coating method Methods 0.000 claims description 7
- 239000004033 plastic Substances 0.000 claims description 7
- 229920003023 plastic Polymers 0.000 claims description 7
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 229920005557 bromobutyl Polymers 0.000 claims description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical group OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 4
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 4
- 239000004743 Polypropylene Substances 0.000 claims description 3
- 230000006870 function Effects 0.000 claims description 3
- 229920001155 polypropylene Polymers 0.000 claims description 3
- 229920005556 chlorobutyl Polymers 0.000 claims description 2
- 229920002725 thermoplastic elastomer Polymers 0.000 claims description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims 1
- 229910052710 silicon Inorganic materials 0.000 claims 1
- 239000010703 silicon Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 33
- 238000000034 method Methods 0.000 abstract description 21
- 208000035475 disorder Diseases 0.000 abstract description 17
- 201000010099 disease Diseases 0.000 abstract description 16
- 239000003795 chemical substances by application Substances 0.000 abstract description 15
- 229940079593 drug Drugs 0.000 abstract description 14
- 229940090044 injection Drugs 0.000 description 65
- 210000001508 eye Anatomy 0.000 description 35
- 238000011282 treatment Methods 0.000 description 26
- 206010014801 endophthalmitis Diseases 0.000 description 13
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 229920000153 Povidone-iodine Polymers 0.000 description 11
- 230000008901 benefit Effects 0.000 description 11
- 230000003115 biocidal effect Effects 0.000 description 11
- 239000006196 drop Substances 0.000 description 11
- 229960001621 povidone-iodine Drugs 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000013618 particulate matter Substances 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 229940092110 macugen Drugs 0.000 description 9
- 239000012530 fluid Substances 0.000 description 8
- 210000001525 retina Anatomy 0.000 description 8
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 7
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 7
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 7
- 238000012377 drug delivery Methods 0.000 description 7
- 210000000744 eyelid Anatomy 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 229940071643 prefilled syringe Drugs 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000002997 ophthalmic solution Substances 0.000 description 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 5
- 229910052721 tungsten Inorganic materials 0.000 description 5
- 239000010937 tungsten Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 210000003786 sclera Anatomy 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 3
- 239000004713 Cyclic olefin copolymer Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000001344 Macular Edema Diseases 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 208000022873 Ocular disease Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004410 intraocular pressure Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 238000009740 moulding (composite fabrication) Methods 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 229940023490 ophthalmic product Drugs 0.000 description 3
- 229940054534 ophthalmic solution Drugs 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000003504 photosensitizing agent Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical group C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 208000032984 Intraoperative Complications Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010025415 Macular oedema Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010057765 Procedural complication Diseases 0.000 description 2
- 208000007135 Retinal Neovascularization Diseases 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 239000003732 agents acting on the eye Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- GINJFDRNADDBIN-FXQIFTODSA-N bilanafos Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCP(C)(O)=O GINJFDRNADDBIN-FXQIFTODSA-N 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 239000000806 elastomer Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 201000010230 macular retinal edema Diseases 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 229910052751 metal Chemical class 0.000 description 2
- 239000002184 metal Chemical class 0.000 description 2
- 230000003232 mucoadhesive effect Effects 0.000 description 2
- 239000002637 mydriatic agent Substances 0.000 description 2
- 230000002911 mydriatic effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229960001802 phenylephrine Drugs 0.000 description 2
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 239000004447 silicone coating Substances 0.000 description 2
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 235000011008 sodium phosphates Nutrition 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- ATNMPCPGYQSWBN-REOHCLBHSA-N (3s)-3-amino-4-chloro-4-oxobutanoic acid Chemical compound ClC(=O)[C@@H](N)CC(O)=O ATNMPCPGYQSWBN-REOHCLBHSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- GGUSQTSTQSHJAH-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-[4-(4-fluorobenzyl)piperidin-1-yl]ethanol Chemical compound C=1C=C(Cl)C=CC=1C(O)CN(CC1)CCC1CC1=CC=C(F)C=C1 GGUSQTSTQSHJAH-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- UIYWFOZZIZEEKJ-XVFCMESISA-N 1-[(2r,3r,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical group F[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 UIYWFOZZIZEEKJ-XVFCMESISA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- QSAVEGSLJISCDF-UHFFFAOYSA-N 2-hydroxy-2-phenylacetic acid (1,2,2,6-tetramethyl-4-piperidinyl) ester Chemical compound C1C(C)(C)N(C)C(C)CC1OC(=O)C(O)C1=CC=CC=C1 QSAVEGSLJISCDF-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- XFHNUTUVALSHOS-UHFFFAOYSA-N 21-hydroxy-5,10,15,20-tetraphenyl-23H-porphyrin-2,3,7-triol Chemical compound Oc1cc2nc1c(-c1ccccc1)c1c(O)c(O)c(c(-c3ccccc3)c3ccc(n3)c(-c3ccccc3)c3ccc([nH]3)c2-c2ccccc2)n1O XFHNUTUVALSHOS-UHFFFAOYSA-N 0.000 description 1
- MHIITNFQDPFSES-UHFFFAOYSA-N 25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1(25),2,4,6,8(27),9,11,13,15,17,19,21,23-tridecaene Chemical class N1C(C=C2C3=CC=CC=C3C(C=C3NC(=C4)C=C3)=N2)=CC=C1C=C1C=CC4=N1 MHIITNFQDPFSES-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 1
- ZTCKUVQHKIMCLI-UHFFFAOYSA-N 3-[2-[2-[2-[2-[2-[2-[bis(4-methoxyphenyl)-phenylmethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy-[di(propan-2-yl)amino]phosphanyl]oxypropanenitrile Chemical compound C1=CC(OC)=CC=C1C(OCCOCCOCCOCCOCCOCCOP(OCCC#N)N(C(C)C)C(C)C)(C=1C=CC(OC)=CC=1)C1=CC=CC=C1 ZTCKUVQHKIMCLI-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- NVZFZMCNALTPBY-XVFCMESISA-N 4-amino-1-[(2r,3r,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical group O=C1N=C(N)C=CN1[C@H]1[C@H](F)[C@H](O)[C@@H](CO)O1 NVZFZMCNALTPBY-XVFCMESISA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 1
- 208000016134 Conjunctival disease Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 206010058202 Cystoid macular oedema Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 208000031969 Eye Hemorrhage Diseases 0.000 description 1
- 208000029728 Eyelid disease Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- ZTVIKZXZYLEVOL-MCOXGKPRSA-N Homatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(O)C1=CC=CC=C1 ZTVIKZXZYLEVOL-MCOXGKPRSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 206010052098 Iodine allergy Diseases 0.000 description 1
- 206010065630 Iris neovascularisation Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- IJHNSHDBIRRJRN-UHFFFAOYSA-N N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241001111421 Pannus Species 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 102000006877 Pituitary Hormones Human genes 0.000 description 1
- 108010047386 Pituitary Hormones Proteins 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 201000010273 Porphyria Cutanea Tarda Diseases 0.000 description 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 206010038903 Retinal vascular occlusion Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102400000160 Thymopentin Human genes 0.000 description 1
- 101800001703 Thymopentin Proteins 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 206010063942 Vitreous loss Diseases 0.000 description 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 1
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- 229960001466 acetohexamide Drugs 0.000 description 1
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 229940099983 activase Drugs 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000000464 adrenergic agent Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000003288 aldose reductase inhibitor Substances 0.000 description 1
- 229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 230000000964 angiostatic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000001455 anti-clotting effect Effects 0.000 description 1
- 230000001512 anti-cytomegaloviral effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940127090 anticoagulant agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000030 antiglaucoma agent Substances 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 229960002028 atropine sulfate Drugs 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940030611 beta-adrenergic blocking agent Drugs 0.000 description 1
- 229940064804 betadine Drugs 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960004324 betaxolol Drugs 0.000 description 1
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960003679 brimonidine Drugs 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 231100000478 corneal permeability Toxicity 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- SKYSRIRYMSLOIN-UHFFFAOYSA-N cyclopentolate Chemical compound C1CCCC1(O)C(C(=O)OCCN(C)C)C1=CC=CC=C1 SKYSRIRYMSLOIN-UHFFFAOYSA-N 0.000 description 1
- 229960001815 cyclopentolate Drugs 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 201000010206 cystoid macular edema Diseases 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
- 208000001763 cytomegalovirus retinitis Diseases 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- YHKBUDZECQDYBR-UHFFFAOYSA-L demecarium bromide Chemical compound [Br-].[Br-].C=1C=CC([N+](C)(C)C)=CC=1OC(=O)N(C)CCCCCCCCCCN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 YHKBUDZECQDYBR-UHFFFAOYSA-L 0.000 description 1
- 229960003715 demecarium bromide Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229940099238 diamox Drugs 0.000 description 1
- GJQPMPFPNINLKP-UHFFFAOYSA-N diclofenamide Chemical compound NS(=O)(=O)C1=CC(Cl)=C(Cl)C(S(N)(=O)=O)=C1 GJQPMPFPNINLKP-UHFFFAOYSA-N 0.000 description 1
- 229960005081 diclofenamide Drugs 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 229960002445 echothiophate iodide Drugs 0.000 description 1
- OVXQHPWHMXOFRD-UHFFFAOYSA-M ecothiopate iodide Chemical compound [I-].CCOP(=O)(OCC)SCC[N+](C)(C)C OVXQHPWHMXOFRD-UHFFFAOYSA-M 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229950005455 eliprodil Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- ISVXIZFUEUVXPG-UHFFFAOYSA-N etiopurpurin Chemical compound CC1C2(CC)C(C(=O)OCC)=CC(C3=NC(C(=C3C)CC)=C3)=C2N=C1C=C(N1)C(CC)=C(C)C1=CC1=C(CC)C(C)=C3N1 ISVXIZFUEUVXPG-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 description 1
- 229960002199 etretinate Drugs 0.000 description 1
- 229950002420 eucatropine Drugs 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229940001501 fibrinolysin Drugs 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229940043075 fluocinolone Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 229960001048 fluorometholone Drugs 0.000 description 1
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960005051 fluostigmine Drugs 0.000 description 1
- 229960001751 fluoxymesterone Drugs 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- DLKYYJFLRUUGHJ-SSJCJZGYSA-A fomivirsen sodium Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([S-])(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)[C@@H](OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)C1 DLKYYJFLRUUGHJ-SSJCJZGYSA-A 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 229960004905 gramicidin Drugs 0.000 description 1
- ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 150000004688 heptahydrates Chemical class 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229960000857 homatropine Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 108010071003 insulin-related factor Proteins 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- DQRZDIMTJNNJHB-UHFFFAOYSA-N isis 2922 Chemical compound O=C1NC(=O)C(C)=CN1C1OC(COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(O)=S)C(OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(S)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)C1 DQRZDIMTJNNJHB-UHFFFAOYSA-N 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 238000012538 light obscuration Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 208000038015 macular disease Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960000582 mepyramine Drugs 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- HNJJXZKZRAWDPF-UHFFFAOYSA-N methapyrilene Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CS1 HNJJXZKZRAWDPF-UHFFFAOYSA-N 0.000 description 1
- FLOSMHQXBMRNHR-DAXSKMNVSA-N methazolamide Chemical compound CC(=O)\N=C1/SC(S(N)(=O)=O)=NN1C FLOSMHQXBMRNHR-DAXSKMNVSA-N 0.000 description 1
- 229960004083 methazolamide Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 239000003604 miotic agent Substances 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 229940087766 mydriacyl Drugs 0.000 description 1
- 229960005016 naphazoline Drugs 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 1
- 229960001907 nitrofurazone Drugs 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960003407 pegaptanib Drugs 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960001190 pheniramine Drugs 0.000 description 1
- XVNVFKZODWAQKN-UHFFFAOYSA-N phosphoric acid;heptahydrate Chemical compound O.O.O.O.O.O.O.OP(O)(O)=O XVNVFKZODWAQKN-UHFFFAOYSA-N 0.000 description 1
- 230000000649 photocoagulation Effects 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 229940109328 photofrin Drugs 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 1
- NUSQOFAKCBLANB-UHFFFAOYSA-N phthalocyanine tetrasulfonic acid Chemical compound C12=CC(S(=O)(=O)O)=CC=C2C(N=C2NC(C3=CC=C(C=C32)S(O)(=O)=O)=N2)=NC1=NC([C]1C=CC(=CC1=1)S(O)(=O)=O)=NC=1N=C1[C]3C=CC(S(O)(=O)=O)=CC3=C2N1 NUSQOFAKCBLANB-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229960004293 porfimer sodium Drugs 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 230000001179 pupillary effect Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 229940011279 ranibizumab injection Drugs 0.000 description 1
- 239000008175 ready-to-use sterile solution Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 210000003994 retinal ganglion cell Anatomy 0.000 description 1
- 208000004644 retinal vein occlusion Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229960002530 sargramostim Drugs 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- JJICLMJFIKGAAU-UHFFFAOYSA-M sodium;2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)purin-6-olate Chemical compound [Na+].NC1=NC([O-])=C2N=CN(COC(CO)CO)C2=N1 JJICLMJFIKGAAU-UHFFFAOYSA-M 0.000 description 1
- RMLUKZWYIKEASN-UHFFFAOYSA-M sodium;2-amino-9-(2-hydroxyethoxymethyl)purin-6-olate Chemical compound [Na+].O=C1[N-]C(N)=NC2=C1N=CN2COCCO RMLUKZWYIKEASN-UHFFFAOYSA-M 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960000654 sulfafurazole Drugs 0.000 description 1
- VACCAVUAMIDAGB-UHFFFAOYSA-N sulfamethizole Chemical compound S1C(C)=NN=C1NS(=O)(=O)C1=CC=C(N)C=C1 VACCAVUAMIDAGB-UHFFFAOYSA-N 0.000 description 1
- 229960005158 sulfamethizole Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000004488 tear evaporation Effects 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 238000004154 testing of material Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 239000012815 thermoplastic material Substances 0.000 description 1
- PSWFFKRAVBDQEG-YGQNSOCVSA-N thymopentin Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PSWFFKRAVBDQEG-YGQNSOCVSA-N 0.000 description 1
- 229960004517 thymopentin Drugs 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229960002277 tolazamide Drugs 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 1
- 229960003962 trifluridine Drugs 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 239000008154 viscoelastic solution Substances 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 229940072358 xylocaine Drugs 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/19—Syringes having more than one chamber, e.g. including a manifold coupling two parallelly aligned syringes through separate channels to a common discharge assembly
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M2005/3201—Coaxially assembled needle cannulas placed on top of another, e.g. needles having different diameters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
- A61M5/2448—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic comprising means for injection of two or more media, e.g. by mixing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3202—Devices for protection of the needle before use, e.g. caps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/34—Constructions for connecting the needle, e.g. to syringe nozzle or needle hub
- A61M5/347—Constructions for connecting the needle, e.g. to syringe nozzle or needle hub rotatable, e.g. bayonet or screw
Landscapes
- Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
The present invention provides a device for use in ophthalmology. In particular, the present invention provides a device for use in intravitreous administration of ocular agents. The present invention also provides methods of delivering one or more drugs to a human eye and methods for treating an ophthalmic disease, disorder, or condition.
Description
OPHTHALMIC SYRINGE
RELATED APPLICATIONS
This application claims priority to U.S. Provisional Application Serial Number 60/717,865 filed September 16, 2005, Attorney Docket No. EYE-036P, which is hereby incorporated in its entirety by reference.
FIELD OF THE INVENTION
The present invention relates to metliods of adininistering ophthalmic medicines and devices related thereto. In particular, the invention relates to intravitreous injection using an ophthahnic syringe and needle.
BACKGROUND OF THE INVENTION
Intravitreous (IVT) injection has been used in the treatment of huinan ocular disease for nearly a century beginning in 1911 as means to introduce air for retinal tamponade and repair of detachment (J. Ohm, Albrecht von Graefes Arch Ophthalmol 1911;
79:442-450).
Over the past two decades, the use of intravitreous injection has gained increasing acceptance in the therapeutic management of many intraocular diseases, particularly disorders affecting the posterior segment of the eye (Jager et al., Retina 24:676-698, 2004). IVT
injection is increasingly being incorporated into management of ocular diseases and the number of approved products for IVT injection is anticipated to grow on the basis of promising results from ongoing clinical studies. Currently formivirsen sodium (Vitravene , Novartis AG, Basel, Switzerland), ranibizumab injection (LucentisTM, Genentech, Inc., South San Francisco, CA) and pegaptanib sodium (Macugeng, (OSI) Eyetech, Inc. NY, NY) are three medicines approved by the Food and Drug Administration as IVT injections.
Advantages of IVT injection of medicines and diagnostics include the achievement of maximum vitreous concentrations while minimizing toxicity attributed to systemic administration. While these advantages are becoming widely appreciated, the ophthalmology community turns its focus to various complications potentially associated with IVT injection.
Risks of IVT injection, some vision threatening, include endophthalmitis, retinal detachinent, iritis/uveitis, inflammation, intraocular hemorrhage, ocular hypertension, hypotony, pneumatic retinopexy, and cataract (R.D. Jager et al., Retina 24:676-698, 2004 and C.N. Ta, Retina, 24:699-705, 2004).
Endophthalmitis is a condition in which the tissues inside the eyeball become inflamed and is generally caused by bacterial infection. The most common sources of bacteria causing postoperative endophthalmitis are believed to be the patient's conjunctiva or eyelids. Unless treated effectively, endophthalmitis can rapidly lead to severe vision loss or blindness. The relative risks of developing postoperative endophthalmitis depend on a number of factors, including the presence of eyelid or conjunctival diseases, the patient's general health, the use of inununosuppressant medications, the type of intraocular surgery, and intraoperative complications. Of these factors, intraoperative complications, particularly breaks in the posterior capsule witli vitreous loss, carry the greatest risk for the development of endophthalmitis.
Although intravitreous injection is a simple procedure with a small wound, it has been demonstrated that bacteria potentially introduced by the procedure are sufficient to induce endophthalmitis, which is likely due to the inability of the vitreous to clear the infectious microorganisms. Other equally plausible explanations for the apparent high risk of endophthalmitis after intravitreous injections may be the very limited sample size as well as publication bias. It is important, nevertlieless, to minimize the risk of developing endoplithalmitis by reducing or eliminating bacteria from the ocular surface at the time of the injection and to strictly adhere to aseptic technique. The use of topical antibiotics has been shown to reduce conjunctival and eyelid bacterial flora, which may in turn also decrease the risk of endophthalmitis.
Because transient increases in intra-ocular pressure (IOP) may cause mild discomfort and can be associated in rare instances with irreversible damage to retinal ganglion cells and/or retinal vascular occlusion, many investigators reported using prophylactic and/or therapeutic measures to prevent increases in IOP after IVT injection. These have included the use of aqueous paracentesis, preoperative treatment with pressure-lowering agents and digital massage or the use of a Honan IOP reducer.
Particulate contaminants present in a drug, in a syringe, or in or on materials used at the time of injection also may have the potential to induce detrimental effects when injected into the vitreous. This has been demonstrated in the case of glove lubricants, wllich are highly inflammatory when injected into the posterior ocular chamber (H.S.
Park, Korean J.
Ophthalinol. 1997; 11:51-59).
Other serious complications rarely occurred after IVT injection, making it difficult, in most instances, to determine whether these were truly injection-related or simply sporadic, unrelated comorbidities.
Serious adverse events are for the most part transient and/or treatable, and the risks of serious adverse events reported after IVT injection is low. Even so, there is a need for improved devices and methods for IVT injection. The risks and benefits of IVT
injection will likely carry increased weight in patient and clinician treatment as more treatment options become available.
Guidelines for IVT injection are continuing to evolve (L.P. Aiello et al., Retina, 24:S3-S19, 2004). For example, povidone iodine and an antibiotic are adnzinistered prior to IVT injection. Also, IVT injections are generally performed with a sterile surgical drape and lid speculum in place and a 27 or 30 gauge needle is typically used with an injection site 3.5-4.0 mm posterior to the limbus.
As new treatment modalities for macular diseases become available, the number of intravitreous injections administered is expected to increase dramatically.
For example, intravitreous injection of the vascular endothelial growth factor (VEGF) inhibitor, Macugen , has become available for the treatment of age-related macular degeneration.
Also, intravitreous injections of triamcinolone acetonide are now coinmonly used for the treatment of macular edema.
The prevalence of endophthalmitis after intravitreous injection of anti-VEGF
agents is unknown. Due to the very limited data regarding the rate of endophthahnitis after intravitreous injections, it is difficult to speculate about the true prevalence of endophthalmitis after these types of procedures. The increased use of intravitreous injections for the delivery of these agents to the retina will provide data regarding the prevalence and risk factors for post-injection endophthalmitis and in the future define a more accurate rate of endophthalmitis.
Drug delivery into the eye is challenging because the anatomy, physiology and biochemistry of the eye includes several defensive barriers that render ocular tissues impervious to foreign substances. Techniques used for administering active agents into the eye include systemic routes, intraocular injections, injections around the eye, intraocular implants, and topical applications. Patient acceptance and safety are key issues that play a key role as to which treatments are used.
Ocular bioavailability of drugs applied topically in formulations such as eye drops is very poor. The absorption of drugs in the eye is severely limited by some protective mechanisms that ensure the proper functioning of the eye, and by other concomitant factors, for exainple: drainage of the instilled solutions; lacrhyrnation, tear evaporation; non-productive absorption/adsoiption such as conjunctival absorption, poor corneal permeability, binding by the lachrymal proteins, and metabolism.
Alternative approaches to delivery include in situ activated gel-forming systems, mucoadhesive formulations, ocular penetration enhancers and ophthalmic inserts. In situ activated gel-for-ming systems are liquid veliicles that undergo a viscosity increase upon instillation in the eye, thus favoring pre-corneal retention. Such a change in viscosity can be triggered by a change in temperature, pH or electrolyte composition.
Mucoadhesive formulations are vehicles containing polymers that adhere via non-covalent bonds to conjunctival inucin, thus ensuring contact of the medication with the pre-comeal tissues until mucin turnover causes elimination of the polymer. Ocular penetration enhancers are mainly surface active agents that are applied to the cornea to enhance the permeability of superficial cells by destroying the cell membranes and causing cell lysis in a dose-dependent manner.
Ophtllalmic inserts are solid devices intended to be placed in the conjunctival sac and to deliver the drug at a comparatively slow rate. One such device is Ocusert , by Alza Corporation, which is a diffusion unit consisting of a drug reservoir enclosed by two release-controlling membranes made of a copolymer. M.F. Saettone provides a review of continued endeavors devoted to ocular delivery. ("Progress and Problems in Ophthalmic Drug Delivery", Business Briefing: Pharmatech, Future Drug Delivery, 2002, 167-171).
Many types of ophthalmic surgeries such as cataract surgery require use of various fluids which are both delivered and removed from the eye over the course of the surgery.
The simultaneous delivery of two or more therapeutics typically requires multiple separate needle penetrations. In areas where bacterial infection and/or structural damage are a concern, the risks associated with multiple injections may become unacceptable.
Multiple injections may be circumvented by using a multi-compartment syringe or a double-barrel syringe.
Administration of multiple viscoelastic solutions witli a multi-compartment syringe is described in US Patent Application Publication No. 2004/0167480. A double-barrel syringe for ophthalmic surgeries is described in US Patent Application Publication No.
2004/0064102.
Such invasive intraocular administrations may not be favorable because they cause 5 patient discomfort and sometimes fear, while risking permanent tissue damage. A device which allows the simultaneous or sequential delivery of a therapeutic while requiring a single needle penetration would significantly reduce any needle associated complications.
SUMMARY OF THE INVENTION
The present invention provides a device for use in ophthalmology. In particular, the present invention provides a device for use in intravitreous administration of ocular agents.
The present invention also provides methods of delivering one or more drugs to a human eye.
In one aspect, the invention relates to ophthalmic drug delivery devices and features a device for delivery of a therapeutic agent to the eye of a mammal.
The invention features a drug delivery device for delivering a therapeutic compound to the eye and drug delivery methods related thereto. The invention also features a syringe for intravitreal delivery and metliods of using the syringe to treat an ophthalmic disease, disorder, or condition.
Other features and advantages of the invention will be apparent from the following description, the drawings, and the claims.
RELATED APPLICATIONS
This application claims priority to U.S. Provisional Application Serial Number 60/717,865 filed September 16, 2005, Attorney Docket No. EYE-036P, which is hereby incorporated in its entirety by reference.
FIELD OF THE INVENTION
The present invention relates to metliods of adininistering ophthalmic medicines and devices related thereto. In particular, the invention relates to intravitreous injection using an ophthahnic syringe and needle.
BACKGROUND OF THE INVENTION
Intravitreous (IVT) injection has been used in the treatment of huinan ocular disease for nearly a century beginning in 1911 as means to introduce air for retinal tamponade and repair of detachment (J. Ohm, Albrecht von Graefes Arch Ophthalmol 1911;
79:442-450).
Over the past two decades, the use of intravitreous injection has gained increasing acceptance in the therapeutic management of many intraocular diseases, particularly disorders affecting the posterior segment of the eye (Jager et al., Retina 24:676-698, 2004). IVT
injection is increasingly being incorporated into management of ocular diseases and the number of approved products for IVT injection is anticipated to grow on the basis of promising results from ongoing clinical studies. Currently formivirsen sodium (Vitravene , Novartis AG, Basel, Switzerland), ranibizumab injection (LucentisTM, Genentech, Inc., South San Francisco, CA) and pegaptanib sodium (Macugeng, (OSI) Eyetech, Inc. NY, NY) are three medicines approved by the Food and Drug Administration as IVT injections.
Advantages of IVT injection of medicines and diagnostics include the achievement of maximum vitreous concentrations while minimizing toxicity attributed to systemic administration. While these advantages are becoming widely appreciated, the ophthalmology community turns its focus to various complications potentially associated with IVT injection.
Risks of IVT injection, some vision threatening, include endophthalmitis, retinal detachinent, iritis/uveitis, inflammation, intraocular hemorrhage, ocular hypertension, hypotony, pneumatic retinopexy, and cataract (R.D. Jager et al., Retina 24:676-698, 2004 and C.N. Ta, Retina, 24:699-705, 2004).
Endophthalmitis is a condition in which the tissues inside the eyeball become inflamed and is generally caused by bacterial infection. The most common sources of bacteria causing postoperative endophthalmitis are believed to be the patient's conjunctiva or eyelids. Unless treated effectively, endophthalmitis can rapidly lead to severe vision loss or blindness. The relative risks of developing postoperative endophthalmitis depend on a number of factors, including the presence of eyelid or conjunctival diseases, the patient's general health, the use of inununosuppressant medications, the type of intraocular surgery, and intraoperative complications. Of these factors, intraoperative complications, particularly breaks in the posterior capsule witli vitreous loss, carry the greatest risk for the development of endophthalmitis.
Although intravitreous injection is a simple procedure with a small wound, it has been demonstrated that bacteria potentially introduced by the procedure are sufficient to induce endophthalmitis, which is likely due to the inability of the vitreous to clear the infectious microorganisms. Other equally plausible explanations for the apparent high risk of endophthalmitis after intravitreous injections may be the very limited sample size as well as publication bias. It is important, nevertlieless, to minimize the risk of developing endoplithalmitis by reducing or eliminating bacteria from the ocular surface at the time of the injection and to strictly adhere to aseptic technique. The use of topical antibiotics has been shown to reduce conjunctival and eyelid bacterial flora, which may in turn also decrease the risk of endophthalmitis.
Because transient increases in intra-ocular pressure (IOP) may cause mild discomfort and can be associated in rare instances with irreversible damage to retinal ganglion cells and/or retinal vascular occlusion, many investigators reported using prophylactic and/or therapeutic measures to prevent increases in IOP after IVT injection. These have included the use of aqueous paracentesis, preoperative treatment with pressure-lowering agents and digital massage or the use of a Honan IOP reducer.
Particulate contaminants present in a drug, in a syringe, or in or on materials used at the time of injection also may have the potential to induce detrimental effects when injected into the vitreous. This has been demonstrated in the case of glove lubricants, wllich are highly inflammatory when injected into the posterior ocular chamber (H.S.
Park, Korean J.
Ophthalinol. 1997; 11:51-59).
Other serious complications rarely occurred after IVT injection, making it difficult, in most instances, to determine whether these were truly injection-related or simply sporadic, unrelated comorbidities.
Serious adverse events are for the most part transient and/or treatable, and the risks of serious adverse events reported after IVT injection is low. Even so, there is a need for improved devices and methods for IVT injection. The risks and benefits of IVT
injection will likely carry increased weight in patient and clinician treatment as more treatment options become available.
Guidelines for IVT injection are continuing to evolve (L.P. Aiello et al., Retina, 24:S3-S19, 2004). For example, povidone iodine and an antibiotic are adnzinistered prior to IVT injection. Also, IVT injections are generally performed with a sterile surgical drape and lid speculum in place and a 27 or 30 gauge needle is typically used with an injection site 3.5-4.0 mm posterior to the limbus.
As new treatment modalities for macular diseases become available, the number of intravitreous injections administered is expected to increase dramatically.
For example, intravitreous injection of the vascular endothelial growth factor (VEGF) inhibitor, Macugen , has become available for the treatment of age-related macular degeneration.
Also, intravitreous injections of triamcinolone acetonide are now coinmonly used for the treatment of macular edema.
The prevalence of endophthalmitis after intravitreous injection of anti-VEGF
agents is unknown. Due to the very limited data regarding the rate of endophthahnitis after intravitreous injections, it is difficult to speculate about the true prevalence of endophthalmitis after these types of procedures. The increased use of intravitreous injections for the delivery of these agents to the retina will provide data regarding the prevalence and risk factors for post-injection endophthalmitis and in the future define a more accurate rate of endophthalmitis.
Drug delivery into the eye is challenging because the anatomy, physiology and biochemistry of the eye includes several defensive barriers that render ocular tissues impervious to foreign substances. Techniques used for administering active agents into the eye include systemic routes, intraocular injections, injections around the eye, intraocular implants, and topical applications. Patient acceptance and safety are key issues that play a key role as to which treatments are used.
Ocular bioavailability of drugs applied topically in formulations such as eye drops is very poor. The absorption of drugs in the eye is severely limited by some protective mechanisms that ensure the proper functioning of the eye, and by other concomitant factors, for exainple: drainage of the instilled solutions; lacrhyrnation, tear evaporation; non-productive absorption/adsoiption such as conjunctival absorption, poor corneal permeability, binding by the lachrymal proteins, and metabolism.
Alternative approaches to delivery include in situ activated gel-forming systems, mucoadhesive formulations, ocular penetration enhancers and ophthalmic inserts. In situ activated gel-for-ming systems are liquid veliicles that undergo a viscosity increase upon instillation in the eye, thus favoring pre-corneal retention. Such a change in viscosity can be triggered by a change in temperature, pH or electrolyte composition.
Mucoadhesive formulations are vehicles containing polymers that adhere via non-covalent bonds to conjunctival inucin, thus ensuring contact of the medication with the pre-comeal tissues until mucin turnover causes elimination of the polymer. Ocular penetration enhancers are mainly surface active agents that are applied to the cornea to enhance the permeability of superficial cells by destroying the cell membranes and causing cell lysis in a dose-dependent manner.
Ophtllalmic inserts are solid devices intended to be placed in the conjunctival sac and to deliver the drug at a comparatively slow rate. One such device is Ocusert , by Alza Corporation, which is a diffusion unit consisting of a drug reservoir enclosed by two release-controlling membranes made of a copolymer. M.F. Saettone provides a review of continued endeavors devoted to ocular delivery. ("Progress and Problems in Ophthalmic Drug Delivery", Business Briefing: Pharmatech, Future Drug Delivery, 2002, 167-171).
Many types of ophthalmic surgeries such as cataract surgery require use of various fluids which are both delivered and removed from the eye over the course of the surgery.
The simultaneous delivery of two or more therapeutics typically requires multiple separate needle penetrations. In areas where bacterial infection and/or structural damage are a concern, the risks associated with multiple injections may become unacceptable.
Multiple injections may be circumvented by using a multi-compartment syringe or a double-barrel syringe.
Administration of multiple viscoelastic solutions witli a multi-compartment syringe is described in US Patent Application Publication No. 2004/0167480. A double-barrel syringe for ophthalmic surgeries is described in US Patent Application Publication No.
2004/0064102.
Such invasive intraocular administrations may not be favorable because they cause 5 patient discomfort and sometimes fear, while risking permanent tissue damage. A device which allows the simultaneous or sequential delivery of a therapeutic while requiring a single needle penetration would significantly reduce any needle associated complications.
SUMMARY OF THE INVENTION
The present invention provides a device for use in ophthalmology. In particular, the present invention provides a device for use in intravitreous administration of ocular agents.
The present invention also provides methods of delivering one or more drugs to a human eye.
In one aspect, the invention relates to ophthalmic drug delivery devices and features a device for delivery of a therapeutic agent to the eye of a mammal.
The invention features a drug delivery device for delivering a therapeutic compound to the eye and drug delivery methods related thereto. The invention also features a syringe for intravitreal delivery and metliods of using the syringe to treat an ophthalmic disease, disorder, or condition.
Other features and advantages of the invention will be apparent from the following description, the drawings, and the claims.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a schematic representation of a needle assembly comprising a luer hub, a cannula and a needle tip having a standard bevel.
Figure 2 is a schematic representation of a needle assembly comprising a luer hub, a cannula and a needle tip shield.
Figure 3 is a schematic representation of a syringe and needle assembly comprising a low dead space hub assembly.
Figure 4 shows drawings of a first embodiment of a double barrel syringe.
Figure 5 shows drawings of a first embodiment of a double barrel syringe.
Figure 6 is a schematic representation of a fluid exchange device.
Figure 7 is a schematic representation of a tandem syringe.
Figure 8 is a graph showing penetration force required by various needles.
DETAILED DESCRIPTION OF THE INVENTION
One aspect provides a syringe useful in ophthalmic applications for delivery of a material into the eye.
Needle Any suitable needle may be used. Suitable needles provide facile penetration of the sclera with minimal injury. A needle typically includes an elongated tube with an outside surface, a proximal end, a distal end and an open bore therethrough. As seen in Figure 1, the needle assembly 20 may have a hub 23 attached to the proximal end of the needle 22 that is used to attach the needle to a syringe. In one embodiment the hub is a Luer hub.
The needle may be attached to the syringe permanently (e.g., staked) or may be attached to the syringe by a Luer fitting. The Luer fitting may be a standard Luer fitting, Luer slip fitting or a Luer lock fitting. The Luer fitting has either a tip (male) or hub (female) component, and provides the ability to insure leak-proof and mechanically secure connections to any other device having a mating Luer fitting. Luer connectors can comprise round and tapered male and matching female mating surfaces. Luer connectors can fonn a locking configuration by adding a threaded locking collar to the male luer connector, which mates with ears on the female luer connector, thereby providing a positive "locked"
connection.
Luer fittings have several advantages. Luer fittings provide compatibility among various medical devices, offering the clinician the benefits of choosing a preferred needle. In addition, Luer-lock connections insure against possibility of needle coming off of the syringe during the injection procedure. Standards for Luer fittings are described in American National Standard ANSI/HIMA MD 70.1-1983 and the International Standard ISO-594-1 and ISO-7886-1.
A non-standard Luer fitting may be used. Examples of non-standard Luer fittings include, but are not limited to, the Tru-LokTM fluid transfer adaptor by Becton Dickinson.
Other non-standard fittings include Tyco Health Care, Kendall Monoject low dead space (LDS) needles featuring tri bevel, anti-coring, stainless steel needles.
Examples of low waste space fittings are found in US Patent Nos. 6,840,291, 5,902,277 5,902,271, 5,902,270 5,902,269 5,782,803, the contents of each are hereby incorporated by reference in its entirety.
The needle may also be attached to the syringe via a ceramic coated tip (CCT) interface, i.e. 'press fit'.
In one embodiment, the needle is beveled and coated with a suitable silicone.
In one embodiment, the needle is a PrecisionGlideg needle available from Becton-Dickenson.
Suitable PrecisionGlide needles include but are not limited to a 1/2 inch 30 gauge needle and a 1/z inch 27 gauge needle. In one embodiment, the needle is a PrecisionGlide shown in Figure 3. Referring to the figure, the needle comprises a polypropylene Luer hub 33 and a stainless steel cannula 34, lubricated with silicone, having a three-bevel point, attached to the hub via an epoxy joint.
The needle tip may have a standard bevel. In one embodiment, the needle may have more than one bevel. In one embodiment, the needle has three bevels. In one einbodiment, the needle has five bevels. Examples of a five-bevel needle are described in US Patent No.
6,629,963, and 6,009,933, US patent Application publication Nos. 2044/0111066, 2004/0030303 and PCT Application No. 2005/016420 In one embodiment, the needle is a coated needle. In one embodiment, the needle is a lubricated needle. The needle optionally includes a lubricious coating applied to and adherent to the outside surface of the tube, as described in US Patent No.
5,911,711.
In one embodiment, the coating is a silicone coating. Any suitable silicone coating may be used. Examples of suitable coatings include, but are not limited to, those available from SurModics, Eden Prairie, MN (see US Patent Nos. 6,706,408, 6,669,994, 6,254,634 and 6,121,027).
In one embodiment the coating is a medicated coating.
Preferably the needle is a 27 gauge needle or smaller. In one embodiment the needle is a 30 gauge needle.
In one embodiment, the needle has a length of less than 1 inch. In another embodiment, the needle has a length of about 0.5 inches.
Needle tip shield As seen in Figure 2, the needle assembly 20 may comprises a needle tip shield enclosing needle 22. Needle 22 is attached to luer hub 23 via epoxy joint 24.
In one embodiment, the tip shield 21 is rigid. Examples of suitable rigid shields include but are not limited to those disclosed in US Patent No. 4,986,818. As depicted in Figure 2, the tip shield is not in contact with the needle tip. Needle tip shields in contact with the needle potentially dull the needle and wipe away any lubrication on the needle. In another einbodiment, the tip shield comprises one or more apertures or is permeable to sterilizing gases.
The apertures may facilitate sterilization by allowing sterilizing gasses or steam to access the interior of the needle shield. In a particular embodiment, the tip shield is synthetic isoprene, ethylene oxide (EtO) or hydrogen peroxide (H202) penneable. In another embodiment, the syringe barrels, stoppers and plunger rod components and assemblies can also be gamma irradiated.
In one embodiment, the needle tip shield comprises a polypropylene. In another embodiment, the needle tip shield comprises a styrene block thermoplastic elastomer.
Penetration Force The needles of the present invention are used for penetration of the scleral tissue for administration of the syringe contents into the vitreous. Preferably the needles require a low penetration force. Preferably the needles require a low penetration force with low variability.
In one embodiment, the needles require a penetration force of less than 500 grains (g). In another embodiment, the needles require a penetration force of less than 100 grams (g). In another embodiment, the needles require a penetration force of less than 50 grams (g).
In one embodiment, the needles require a penetration force with a variability range of +/- 20 %. In one embodiment, the needles require a penetration force witli a variability range of +/- 50 g. In anotller embodiment, the needles require a penetration force with a variability range of +/- 20 g In one embodiment, the penetration force is reduced by reducing the needles coefficient of friction. In one einbodiment the penetration force is reduced by using a lubricious coating on the needle.
Syringe The syringe barrel is typically made of glass or a thermoplastic material. In one embodiment the syringe is a 1 mL Type I glass barrel syringe sealed with a bromobutyl rubber stopper. Exainples of pre-filled syringes are found in US Patent No.
4,252,11 S. In one embodiment the syringe is a BD Hypak SCF syringe. In a particular einbodiment, the syringe is a single dose, pre-filled syringe. In one embodiment, the syringe barrel has a volume of 1 mL or less. In a particular embodiment, the syringe barrel has a microliter volume. The syringe barrels of the present invention may further be provided with graduations to assist in precision filling of the barrel.
In one einbodiment, the syringe is a plastic syringe. In another einbodiment, the syringe comprises a cyclic olefin copolymer (COC). In another embodiment the cyclic olefin copolymer is TopPac (Schott).
In another embodiment, the final Luer formation is made using a platinum wire.
In a particular embodiment, the syringe is substantially free of tungsten. Staked needle production requires a small hole and seat for gluing in the needle. The small hole requires a high temperature tungsten pin. Some of the tungsten pin material may shed into the glass during processing. Luer lock syringes are alternatively formed using a platinum pin material.
The platinum may not leave a significant residue in the glass as compared to tungsten.
Optimal particulate matter concentrations may be achieved primarily through strict control of the environment and material cleanliness.
Volume The ophthalmic injection solutions of the present invention are useful as inicroliter 5 ( L)-volume injections. Microliter ( L)-volume injections may also be referred to as "ultra-low volume injections". In one embodiment, the ophthalmic injection solution to be delivered has a volunie of about 1.0 mL (1000 [tL) or less. In another embodiment the ophthalmic injection solution to be delivered has a volume of about 200 L or less. In another embodiment the ophthalmic injection solution to be delivered has a volume of about 10 100 L or less. In another embodiment the ophthalmic injection solution to be delivered has a volume of about 90 L. In another embodiment the ophthalmic injection solution to be delivered has a volume of about 50 L.
,Sub-Visible Particulate Matter The ophthalmic injection solutions of the present invention, including solutions constituted from sterile solids intended for parenteral use, as used herein are substantially free from particles that can be observed on visual inspection. There are also strict controls on sub-visible particulate matter for ophthalmic injections. The ophthalmic injection solutions of the present invention can be tested by a light obscuration procedure or may be tested by a microscopic procedure as described in USP Chapter <788>. United States Pharmacopoeia (USP) Chapters <788> Particulate Matter in Injections and <789> Particulate Matter in Ophthalmic Solutions describe physical tests for the purpose of enumerating extraneous particles within specific size ranges. The United States Pharmacopoeia, 28 th revision and the National Formulary, 23'd edition (USP28-NF23), The United States Pharmacopeial Convention, Inc (2005), is hereby incorporated by reference in its entirety.
In one embodiinent, the ophthahnic solution contained within the syringe of the present invention has a l0 m-size or larger sub-visible particulate count of less than or equal to about 60 particles per mL, a 25 m-size or larger sub-visible particulate count of less than or equal to about 10 particles per mL, or a 50gm-size or larger sub-visible particulate count of less than or equal to about 5 particles per mL. In one particular embodiment, the concentration of sub-visible particulate matter is less than or equal to about 150 ppb.
Figure 1 is a schematic representation of a needle assembly comprising a luer hub, a cannula and a needle tip having a standard bevel.
Figure 2 is a schematic representation of a needle assembly comprising a luer hub, a cannula and a needle tip shield.
Figure 3 is a schematic representation of a syringe and needle assembly comprising a low dead space hub assembly.
Figure 4 shows drawings of a first embodiment of a double barrel syringe.
Figure 5 shows drawings of a first embodiment of a double barrel syringe.
Figure 6 is a schematic representation of a fluid exchange device.
Figure 7 is a schematic representation of a tandem syringe.
Figure 8 is a graph showing penetration force required by various needles.
DETAILED DESCRIPTION OF THE INVENTION
One aspect provides a syringe useful in ophthalmic applications for delivery of a material into the eye.
Needle Any suitable needle may be used. Suitable needles provide facile penetration of the sclera with minimal injury. A needle typically includes an elongated tube with an outside surface, a proximal end, a distal end and an open bore therethrough. As seen in Figure 1, the needle assembly 20 may have a hub 23 attached to the proximal end of the needle 22 that is used to attach the needle to a syringe. In one embodiment the hub is a Luer hub.
The needle may be attached to the syringe permanently (e.g., staked) or may be attached to the syringe by a Luer fitting. The Luer fitting may be a standard Luer fitting, Luer slip fitting or a Luer lock fitting. The Luer fitting has either a tip (male) or hub (female) component, and provides the ability to insure leak-proof and mechanically secure connections to any other device having a mating Luer fitting. Luer connectors can comprise round and tapered male and matching female mating surfaces. Luer connectors can fonn a locking configuration by adding a threaded locking collar to the male luer connector, which mates with ears on the female luer connector, thereby providing a positive "locked"
connection.
Luer fittings have several advantages. Luer fittings provide compatibility among various medical devices, offering the clinician the benefits of choosing a preferred needle. In addition, Luer-lock connections insure against possibility of needle coming off of the syringe during the injection procedure. Standards for Luer fittings are described in American National Standard ANSI/HIMA MD 70.1-1983 and the International Standard ISO-594-1 and ISO-7886-1.
A non-standard Luer fitting may be used. Examples of non-standard Luer fittings include, but are not limited to, the Tru-LokTM fluid transfer adaptor by Becton Dickinson.
Other non-standard fittings include Tyco Health Care, Kendall Monoject low dead space (LDS) needles featuring tri bevel, anti-coring, stainless steel needles.
Examples of low waste space fittings are found in US Patent Nos. 6,840,291, 5,902,277 5,902,271, 5,902,270 5,902,269 5,782,803, the contents of each are hereby incorporated by reference in its entirety.
The needle may also be attached to the syringe via a ceramic coated tip (CCT) interface, i.e. 'press fit'.
In one embodiment, the needle is beveled and coated with a suitable silicone.
In one embodiment, the needle is a PrecisionGlideg needle available from Becton-Dickenson.
Suitable PrecisionGlide needles include but are not limited to a 1/2 inch 30 gauge needle and a 1/z inch 27 gauge needle. In one embodiment, the needle is a PrecisionGlide shown in Figure 3. Referring to the figure, the needle comprises a polypropylene Luer hub 33 and a stainless steel cannula 34, lubricated with silicone, having a three-bevel point, attached to the hub via an epoxy joint.
The needle tip may have a standard bevel. In one embodiment, the needle may have more than one bevel. In one embodiment, the needle has three bevels. In one einbodiment, the needle has five bevels. Examples of a five-bevel needle are described in US Patent No.
6,629,963, and 6,009,933, US patent Application publication Nos. 2044/0111066, 2004/0030303 and PCT Application No. 2005/016420 In one embodiment, the needle is a coated needle. In one embodiment, the needle is a lubricated needle. The needle optionally includes a lubricious coating applied to and adherent to the outside surface of the tube, as described in US Patent No.
5,911,711.
In one embodiment, the coating is a silicone coating. Any suitable silicone coating may be used. Examples of suitable coatings include, but are not limited to, those available from SurModics, Eden Prairie, MN (see US Patent Nos. 6,706,408, 6,669,994, 6,254,634 and 6,121,027).
In one embodiment the coating is a medicated coating.
Preferably the needle is a 27 gauge needle or smaller. In one embodiment the needle is a 30 gauge needle.
In one embodiment, the needle has a length of less than 1 inch. In another embodiment, the needle has a length of about 0.5 inches.
Needle tip shield As seen in Figure 2, the needle assembly 20 may comprises a needle tip shield enclosing needle 22. Needle 22 is attached to luer hub 23 via epoxy joint 24.
In one embodiment, the tip shield 21 is rigid. Examples of suitable rigid shields include but are not limited to those disclosed in US Patent No. 4,986,818. As depicted in Figure 2, the tip shield is not in contact with the needle tip. Needle tip shields in contact with the needle potentially dull the needle and wipe away any lubrication on the needle. In another einbodiment, the tip shield comprises one or more apertures or is permeable to sterilizing gases.
The apertures may facilitate sterilization by allowing sterilizing gasses or steam to access the interior of the needle shield. In a particular embodiment, the tip shield is synthetic isoprene, ethylene oxide (EtO) or hydrogen peroxide (H202) penneable. In another embodiment, the syringe barrels, stoppers and plunger rod components and assemblies can also be gamma irradiated.
In one embodiment, the needle tip shield comprises a polypropylene. In another embodiment, the needle tip shield comprises a styrene block thermoplastic elastomer.
Penetration Force The needles of the present invention are used for penetration of the scleral tissue for administration of the syringe contents into the vitreous. Preferably the needles require a low penetration force. Preferably the needles require a low penetration force with low variability.
In one embodiment, the needles require a penetration force of less than 500 grains (g). In another embodiment, the needles require a penetration force of less than 100 grams (g). In another embodiment, the needles require a penetration force of less than 50 grams (g).
In one embodiment, the needles require a penetration force with a variability range of +/- 20 %. In one embodiment, the needles require a penetration force witli a variability range of +/- 50 g. In anotller embodiment, the needles require a penetration force with a variability range of +/- 20 g In one embodiment, the penetration force is reduced by reducing the needles coefficient of friction. In one einbodiment the penetration force is reduced by using a lubricious coating on the needle.
Syringe The syringe barrel is typically made of glass or a thermoplastic material. In one embodiment the syringe is a 1 mL Type I glass barrel syringe sealed with a bromobutyl rubber stopper. Exainples of pre-filled syringes are found in US Patent No.
4,252,11 S. In one embodiment the syringe is a BD Hypak SCF syringe. In a particular einbodiment, the syringe is a single dose, pre-filled syringe. In one embodiment, the syringe barrel has a volume of 1 mL or less. In a particular embodiment, the syringe barrel has a microliter volume. The syringe barrels of the present invention may further be provided with graduations to assist in precision filling of the barrel.
In one einbodiment, the syringe is a plastic syringe. In another einbodiment, the syringe comprises a cyclic olefin copolymer (COC). In another embodiment the cyclic olefin copolymer is TopPac (Schott).
In another embodiment, the final Luer formation is made using a platinum wire.
In a particular embodiment, the syringe is substantially free of tungsten. Staked needle production requires a small hole and seat for gluing in the needle. The small hole requires a high temperature tungsten pin. Some of the tungsten pin material may shed into the glass during processing. Luer lock syringes are alternatively formed using a platinum pin material.
The platinum may not leave a significant residue in the glass as compared to tungsten.
Optimal particulate matter concentrations may be achieved primarily through strict control of the environment and material cleanliness.
Volume The ophthalmic injection solutions of the present invention are useful as inicroliter 5 ( L)-volume injections. Microliter ( L)-volume injections may also be referred to as "ultra-low volume injections". In one embodiment, the ophthalmic injection solution to be delivered has a volunie of about 1.0 mL (1000 [tL) or less. In another embodiment the ophthalmic injection solution to be delivered has a volume of about 200 L or less. In another embodiment the ophthalmic injection solution to be delivered has a volume of about 10 100 L or less. In another embodiment the ophthalmic injection solution to be delivered has a volume of about 90 L. In another embodiment the ophthalmic injection solution to be delivered has a volume of about 50 L.
,Sub-Visible Particulate Matter The ophthalmic injection solutions of the present invention, including solutions constituted from sterile solids intended for parenteral use, as used herein are substantially free from particles that can be observed on visual inspection. There are also strict controls on sub-visible particulate matter for ophthalmic injections. The ophthalmic injection solutions of the present invention can be tested by a light obscuration procedure or may be tested by a microscopic procedure as described in USP Chapter <788>. United States Pharmacopoeia (USP) Chapters <788> Particulate Matter in Injections and <789> Particulate Matter in Ophthalmic Solutions describe physical tests for the purpose of enumerating extraneous particles within specific size ranges. The United States Pharmacopoeia, 28 th revision and the National Formulary, 23'd edition (USP28-NF23), The United States Pharmacopeial Convention, Inc (2005), is hereby incorporated by reference in its entirety.
In one embodiinent, the ophthahnic solution contained within the syringe of the present invention has a l0 m-size or larger sub-visible particulate count of less than or equal to about 60 particles per mL, a 25 m-size or larger sub-visible particulate count of less than or equal to about 10 particles per mL, or a 50gm-size or larger sub-visible particulate count of less than or equal to about 5 particles per mL. In one particular embodiment, the concentration of sub-visible particulate matter is less than or equal to about 150 ppb.
In one embodiment the ophthalmic solution contained within the syringe of the present invention is subject to the particulate matter limits set forth in USP
<789> wherein the average number of particles present in the units tested does not exceed the values listed in Table 1.
Table 1.
Diameter >10 m >25 m >50 m Number of particles 50 per mL 5 per mL 2 per mL
In one embodiment, the ophthalmic solution contained within the syringe of the present invention has a 10 m-size or larger sub-visible particulate count of less than or equal to about 20 particles per mL, a 25 m-size or larger sub-visible particulate count of less than or equal to about 5 particles per mL, or a 50 m-size or larger sub-visible particulate count of less than or equal to about 2 particles per mL. In one particular embodiment, the concentration of sub-visible particulate matter contained within the syringe of the present invention is less than or equal to about 150 ppb.
Waste volume As represented in Figure 3, the syringe assembly has a low waste space, which is defined as the volume located in the syringe tip 31 of syringe barre132, needle hub 33 and needle cannula 34. The International Standard ISO-7886-1 identifies the maximum waste space for a 3ml syringe tip to be 0.07 mL.
In a particular embodiment, the needle/syringe combination of the present invention has a low waste space. Examples of low waste space fittings are found in US
Patent Nos. 6,840,291, 5,902,277 5,902,271, 5,902,270 5,902,269 5,782,803, the contents of each is hereby incorporated by reference in its entirety. An example of a needle/syringe combination having a low waste space includes Tru-lokTM fluid transfer adaptors by Becton Dickinson (US Patent No. 6,840,291) and Monoject0 low dead space (LDS) needles Tyco Health Care, Kendall (catalog Nos. 1188005058 and 1188001112) featuring tri bevel, anti-coring, stainless steel needles.
The needle/syringe combination of the present invention has a waste space of less than 0.1 mL. In one embodiment, the waste space is less than 0.05 mL. In another embodiment, the waste space is approx. 50-60 L. In one einbodiment, the waste space for the 1 mL Hypak Luer tip syringe is from about 0.040 to about 0.050 mL. In another embodiment, the waste space is less than 0.001 mL.
Syringe tip cap The syringe assembly may comprise a syringe tip cap. The syringe tip cap is used to seal the barrel of a prefilled syringe. In one embodiment, the syringe tip cap is a plastic rigid tip cap. Examples of suitable syringe tip caps include, but are not limited to, those found in US Patent Nos. 6,190,364; 6,196,998; 6,520,935 and 5,833,653; US patent Application Publication No. 2004/0215148 and US design patent Nos. 457954S1 and 493526S1.
In one embodiment, the rigid tip cap is an elastomeric formulation comprising an elastomer, reinforcement and a curing system. In another embodiment, the elastomer is a synthetic isoprene blend, the reinforcement is an inert material, and the curing system is a resin. In another embodiment, the syringe tip cap comprises a chloro/bromobutyl rubber stopper.
Multiple barrel syringe Another aspect of the invention provides a syringe comprising more than one barrel.
The multiple barrel syringe may permit simultaneous, selective or sequential delivery of one or more different materials.
In one embodiment the syringe comprises a first and second barrel positioned in side-by-side relationship including a first and second plunger for telescoping movement within their respective chambers (see US Patent Application Publication No.
2004/0064102, which is herby incorporated by reference in its entirety). The plungers are optionally connected to a common handle allowing for the dispensing of the inaterials from the two chambers simultaneously at the saine rate, as disclosed, for example, in US Patent No.
5,792,103. In another embodiment, the plungers are detachably connected to the plunger stopper.
<789> wherein the average number of particles present in the units tested does not exceed the values listed in Table 1.
Table 1.
Diameter >10 m >25 m >50 m Number of particles 50 per mL 5 per mL 2 per mL
In one embodiment, the ophthalmic solution contained within the syringe of the present invention has a 10 m-size or larger sub-visible particulate count of less than or equal to about 20 particles per mL, a 25 m-size or larger sub-visible particulate count of less than or equal to about 5 particles per mL, or a 50 m-size or larger sub-visible particulate count of less than or equal to about 2 particles per mL. In one particular embodiment, the concentration of sub-visible particulate matter contained within the syringe of the present invention is less than or equal to about 150 ppb.
Waste volume As represented in Figure 3, the syringe assembly has a low waste space, which is defined as the volume located in the syringe tip 31 of syringe barre132, needle hub 33 and needle cannula 34. The International Standard ISO-7886-1 identifies the maximum waste space for a 3ml syringe tip to be 0.07 mL.
In a particular embodiment, the needle/syringe combination of the present invention has a low waste space. Examples of low waste space fittings are found in US
Patent Nos. 6,840,291, 5,902,277 5,902,271, 5,902,270 5,902,269 5,782,803, the contents of each is hereby incorporated by reference in its entirety. An example of a needle/syringe combination having a low waste space includes Tru-lokTM fluid transfer adaptors by Becton Dickinson (US Patent No. 6,840,291) and Monoject0 low dead space (LDS) needles Tyco Health Care, Kendall (catalog Nos. 1188005058 and 1188001112) featuring tri bevel, anti-coring, stainless steel needles.
The needle/syringe combination of the present invention has a waste space of less than 0.1 mL. In one embodiment, the waste space is less than 0.05 mL. In another embodiment, the waste space is approx. 50-60 L. In one einbodiment, the waste space for the 1 mL Hypak Luer tip syringe is from about 0.040 to about 0.050 mL. In another embodiment, the waste space is less than 0.001 mL.
Syringe tip cap The syringe assembly may comprise a syringe tip cap. The syringe tip cap is used to seal the barrel of a prefilled syringe. In one embodiment, the syringe tip cap is a plastic rigid tip cap. Examples of suitable syringe tip caps include, but are not limited to, those found in US Patent Nos. 6,190,364; 6,196,998; 6,520,935 and 5,833,653; US patent Application Publication No. 2004/0215148 and US design patent Nos. 457954S1 and 493526S1.
In one embodiment, the rigid tip cap is an elastomeric formulation comprising an elastomer, reinforcement and a curing system. In another embodiment, the elastomer is a synthetic isoprene blend, the reinforcement is an inert material, and the curing system is a resin. In another embodiment, the syringe tip cap comprises a chloro/bromobutyl rubber stopper.
Multiple barrel syringe Another aspect of the invention provides a syringe comprising more than one barrel.
The multiple barrel syringe may permit simultaneous, selective or sequential delivery of one or more different materials.
In one embodiment the syringe comprises a first and second barrel positioned in side-by-side relationship including a first and second plunger for telescoping movement within their respective chambers (see US Patent Application Publication No.
2004/0064102, which is herby incorporated by reference in its entirety). The plungers are optionally connected to a common handle allowing for the dispensing of the inaterials from the two chambers simultaneously at the saine rate, as disclosed, for example, in US Patent No.
5,792,103. In another embodiment, the plungers are detachably connected to the plunger stopper.
Figures 4 and 5 show examples of dual barrel syringes for the simultaneous or sequential delivery of two or more therapeutic agents. The syringe includes a first barrel, a second barrel, and one or more needles. Each barrel contains a therapeutic agent dissolved or suspended in a liquid formulation. Referring now to the drawings, there is seen in Figures 4 and 5 first and second embodiments of the double barrel syringe which differ in the respect that the first embodiment (Figure 4) is configured for direct filling of the first and second materials inside their respective barrels wllile the second embodiinent (Figures 5) is configured for insertion of pre-filled first and second carpules into the first and second barrels, respectively.
Referring to the first embodiment shown in Figure 4, the syringe coinprises first and second barrels 41, 42 each having an internal chamber 43, 44 for holding a quantity of first and second, liquefied materials therein, respectively. The first and second barrels 41, 42 are arranged in side-by-side relationship with each other. First and second plungers 45, 46 are positioned for sliding within the first and second barrels 41, 42 for telescoping movement therein, respectively. The syringe tip 47 is located adjacent the distal ends of the first and second barrels 41, 42 and is in common, fluid cominunication therewith via exit orifices 48 and 49. The exit orifices 48 and 49 provide the pathway for the first and second materials, respectively, to tip 47 and thereby allowing passage of the first and second therethrough. Tip 47 may be in the form of a needle directly attached to the syringe body, or may be in the form of a cannula which is attached to the syringe body via a Luer lock.
Referring to the second einbodiment shown in Figure 5, the syringe coinprises first and second carpules 51, 52 removably insertable within said first and second barrels 53, 54, respectively. First and second syringe needles 55, 561ocated in the first and second barrels 53, 54 adjacent the distal ends thereof. As such, upon fully inserting the first and second carpules 51, 52 in the first and second barrels 53, 54, the first and second syringe needles 55, 56 pierce the carpule plug provided at the respective carpule distal end. The first and second needles 55, 56 extend into the tip 57.
A single needle with two or more hollow bores may perform both injections or multiple needles may be used. When one needle is employed, two cannulas, one affixed to one of each barrel, may lead to the one needle. Alternatively, when one needle is employed, the hollow bores may be arranged in a concentric pattern. In such a concentric pattern, one bore is for introduction of a first fluid into the vitreous, and one bore is for introduction of second fluid into the vitreous. When two needles are employed, a second needle may be attached to the exterior of a first needle. Needles may be manufactured from standard materials, e.g., stainless steel, by methods known in the art.
PCT Publication No. WO 2004/073765 describes, in part, a Fluid Exchange System (FES) which is designed to remove a specific volume from a closed system and sequentially deliver a measured voluine. By replacing the vacuum chamber with a housing that can accept a pre-filled syringe and removing the air vents (manifolds) an addition tllerapeutic may be delivered utilizing the original needle penetration. Additional syringe housings could also be added to allow for multiple sequential adininistrations. Figure 6 illustrates an apparatus comprising a first and second housing 61, 62 capable of accepting a first and second prefilled syringe 63, 64.
In one aspect, multiple medicaments can be administered using a tandem syringe. A
tandein syringe typically comprises two or more compartments within one external barrel.
Examples of tandem syringes include but are not limited to those found in US
Patent Nos.
4,313,440; 4,715,854; 5,102,388; 5,298,024; 6,132,400; and US Patent Application Publication No. 2004/0167480, each of which is herby incorporated by reference in its entirety.
In one embodiment, the tandem syringe comprises an outer first coinpartment including a first sealing member and an inner second compartment in which the first sealing member functions as the plunger for the outer first compartment (see Figure 7). Referring to Figure 7, the outer first compartment 71 is filled with a first injection solution. The inner second compartment 72 is filled with a second injection solution. The inner second compartment comprises a first sealing member 73 and functions as the piston for the first compartment. When the first injection solution in completely administered, the first sealing member 73 is pierced using a piercing device 74 at the distal end of the outer first chamber.
Once the first sealing member 73 is pierced, the second injection solution is administered by pushing stopper 75 with plunger 77 thereby forcing the second injection solution past stopper 73 and out through the needle 76.
Each coinpartment may be pre-filled with its injection solution separately providing for storage of the injection solutions without mixing or contact with each other.
In one embodiment compartment 71 (inner compartment) contains the final solution to be injected. Coinpartment 71 is first loaded separately, then assembled with the main housing forming compartment 72. Compartment 72 in then loaded with the first solution to be injected.
5 Advantages The syringes of the present invention have several advantages. Advantages include the benefits of ease of use, flexibility, cost effectiveness, patient comfort and safety. An advantage of using a non-fixed needle/syringe combination, such as one using a Luer fitting, as described herein is the allowance for a choice of application needle. For example, a 10 practitioner may select either a 27 or 30 gauge disposable needle. A non-fixed needle is typically sharper than a fixed needle because the non-fixed needle will not be susceptible to dulling as a result of contact with the sheath needed for a fixed needle pre-filled syringe.
Sharper needles reduce patient discomfort and reduce the risk of infection.
Definitions 15 The grammatically correct and preferred terin "intravitreous" is used herein and in the art. The term "intravitreal" is used colloquially as an alternative to the term "intravitreous"
for injections into the eye's vitreous humor between the lens and the retina.
"Particulate matter" includes mobile, randomly sourced, extraneous substances, other than gas bubbles, that cannot be quantitated by chemical analysis because of the small amount of material they represent or because of their heterogeneous composition.
The portion of the device that is toward the practitioner is tenned "proximal"
and the portion of the device that is toward the patient is termed "distal."
"Penetration force" is the measure of force applied to the needle prior to the needle cutting the tissue. Penetration force is typically measured throughout the art in grams (g).
"Drag force" is a measure of force applied to the needle required to continue the penetration into the tissue.
Referring to the first embodiment shown in Figure 4, the syringe coinprises first and second barrels 41, 42 each having an internal chamber 43, 44 for holding a quantity of first and second, liquefied materials therein, respectively. The first and second barrels 41, 42 are arranged in side-by-side relationship with each other. First and second plungers 45, 46 are positioned for sliding within the first and second barrels 41, 42 for telescoping movement therein, respectively. The syringe tip 47 is located adjacent the distal ends of the first and second barrels 41, 42 and is in common, fluid cominunication therewith via exit orifices 48 and 49. The exit orifices 48 and 49 provide the pathway for the first and second materials, respectively, to tip 47 and thereby allowing passage of the first and second therethrough. Tip 47 may be in the form of a needle directly attached to the syringe body, or may be in the form of a cannula which is attached to the syringe body via a Luer lock.
Referring to the second einbodiment shown in Figure 5, the syringe coinprises first and second carpules 51, 52 removably insertable within said first and second barrels 53, 54, respectively. First and second syringe needles 55, 561ocated in the first and second barrels 53, 54 adjacent the distal ends thereof. As such, upon fully inserting the first and second carpules 51, 52 in the first and second barrels 53, 54, the first and second syringe needles 55, 56 pierce the carpule plug provided at the respective carpule distal end. The first and second needles 55, 56 extend into the tip 57.
A single needle with two or more hollow bores may perform both injections or multiple needles may be used. When one needle is employed, two cannulas, one affixed to one of each barrel, may lead to the one needle. Alternatively, when one needle is employed, the hollow bores may be arranged in a concentric pattern. In such a concentric pattern, one bore is for introduction of a first fluid into the vitreous, and one bore is for introduction of second fluid into the vitreous. When two needles are employed, a second needle may be attached to the exterior of a first needle. Needles may be manufactured from standard materials, e.g., stainless steel, by methods known in the art.
PCT Publication No. WO 2004/073765 describes, in part, a Fluid Exchange System (FES) which is designed to remove a specific volume from a closed system and sequentially deliver a measured voluine. By replacing the vacuum chamber with a housing that can accept a pre-filled syringe and removing the air vents (manifolds) an addition tllerapeutic may be delivered utilizing the original needle penetration. Additional syringe housings could also be added to allow for multiple sequential adininistrations. Figure 6 illustrates an apparatus comprising a first and second housing 61, 62 capable of accepting a first and second prefilled syringe 63, 64.
In one aspect, multiple medicaments can be administered using a tandem syringe. A
tandein syringe typically comprises two or more compartments within one external barrel.
Examples of tandem syringes include but are not limited to those found in US
Patent Nos.
4,313,440; 4,715,854; 5,102,388; 5,298,024; 6,132,400; and US Patent Application Publication No. 2004/0167480, each of which is herby incorporated by reference in its entirety.
In one embodiment, the tandem syringe comprises an outer first coinpartment including a first sealing member and an inner second compartment in which the first sealing member functions as the plunger for the outer first compartment (see Figure 7). Referring to Figure 7, the outer first compartment 71 is filled with a first injection solution. The inner second compartment 72 is filled with a second injection solution. The inner second compartment comprises a first sealing member 73 and functions as the piston for the first compartment. When the first injection solution in completely administered, the first sealing member 73 is pierced using a piercing device 74 at the distal end of the outer first chamber.
Once the first sealing member 73 is pierced, the second injection solution is administered by pushing stopper 75 with plunger 77 thereby forcing the second injection solution past stopper 73 and out through the needle 76.
Each coinpartment may be pre-filled with its injection solution separately providing for storage of the injection solutions without mixing or contact with each other.
In one embodiment compartment 71 (inner compartment) contains the final solution to be injected. Coinpartment 71 is first loaded separately, then assembled with the main housing forming compartment 72. Compartment 72 in then loaded with the first solution to be injected.
5 Advantages The syringes of the present invention have several advantages. Advantages include the benefits of ease of use, flexibility, cost effectiveness, patient comfort and safety. An advantage of using a non-fixed needle/syringe combination, such as one using a Luer fitting, as described herein is the allowance for a choice of application needle. For example, a 10 practitioner may select either a 27 or 30 gauge disposable needle. A non-fixed needle is typically sharper than a fixed needle because the non-fixed needle will not be susceptible to dulling as a result of contact with the sheath needed for a fixed needle pre-filled syringe.
Sharper needles reduce patient discomfort and reduce the risk of infection.
Definitions 15 The grammatically correct and preferred terin "intravitreous" is used herein and in the art. The term "intravitreal" is used colloquially as an alternative to the term "intravitreous"
for injections into the eye's vitreous humor between the lens and the retina.
"Particulate matter" includes mobile, randomly sourced, extraneous substances, other than gas bubbles, that cannot be quantitated by chemical analysis because of the small amount of material they represent or because of their heterogeneous composition.
The portion of the device that is toward the practitioner is tenned "proximal"
and the portion of the device that is toward the patient is termed "distal."
"Penetration force" is the measure of force applied to the needle prior to the needle cutting the tissue. Penetration force is typically measured throughout the art in grams (g).
"Drag force" is a measure of force applied to the needle required to continue the penetration into the tissue.
An "Injection" is a preparation intended for parenteral administration.
Injections include, but are not limited to, liquid preparations that are drug substances or solutions/suspensions thereof.
By "substantially constant pressure" is meant pressure that is constant with minor, teinporary variations due to filling, emptying, or a change in osmotic pressure of the surrounding liquid.
"Parenteral" articles are preparations intended for injection through the skin or other external boundary tissue, rather than through the alimentary canal, so that the active substances they contain are administered, using gravity or force, directly into a blood vessel, organ, tissue, or lesion. Parenteral articles are prepared by metllods designed to ensure that they meet Pharmacopeial requirements for sterility, pyrogens, particulate matter, and other contaminants (USP Chapter 1).
The designation "Small-Volume Injection" applies to an injection that is packaged in containers labeled as containing 100 mL or less.
The designation "Microliter-volume Injection" or "Ultra-Low-Volume Injection"
applies to an Injection that is packaged in containers labeled as containing 1.0 mL (1000 L) or less.
As used herein, the term "dead space" or "Waste space" is the volume of injection solution within the syringe/needle asseinbly containing any residual injection solution present following an injection that does not get evacuated from the syringe during the injection.
By "therapeutic agent" is meant any compound or mixture of compounds that provide a therapeutic effect for one or more diseases, disorders, or conditions. Such compounds include, without limitation, small organic or inorganic molecules, proteins (e.g., antibodies), peptides, lipids (e.g., steroids) and nucleic acids (e.g., aptamers).
Therapeutic agents are, for example, antibiotics, analgesics, anti-inflammatory compounds, or any other compound for the treatment of a disease, disorder, or condition.
By "treating" is meant the medical management of a patient with the intent that a cure, amelioration, or prevention of a disease, pathological condition, or disorder will result. This tenn includes active treatment, that is, treatinent directed specifically toward improvement of a disease, pathological condition, or disorder, and also includes causal treatment, that is, treatment directed toward removal of the cause of the disease, pathological condition, or disorder. In addition, this tenn includes palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the disease, pathological condition, or disorder;
preventive treatment, that is, treatment directed to prevention of the disease, patliological condition, or disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the disease, pathological condition, or disorder. The term "treating" also includes symptomatic treatment, that is, treatment directed toward constitutional syiuptoms of the disease, pathological condition, or disorder.
Ophthalmic solutions are sterile solutions, essentially free from foreign particles, suitably compounded and packaged for instillation or injection into the eye.
Preparation of an ophthalmic solution requires careful consideration of such factors as the inherent toxicity of the drug itself, isotonicity value, the need for buffering agents, the need for a preservative (and, if needed, its selection), sterilization, and proper packaging.
While specific reference has been made to the use of the devices of the present invention to administer therapeutic agents to the eye, it is to be understood that the present invention can be used to deliver a therapeutic agent to any desired site, including, but not limited to, intraorbital, intraocular, intraaural, intratympanic, intrathecal, intracavitary, peritumoral, intratumoral, intraspinal, epidural, intracranial, and intracardial.
A device of the invention may be used in the treatment of any eye disease. A
device of the invention may also be used to direct a therapeutic agent to a particular eye tissue, e.g., the retina or the choroid. The therapeutic agent or combination of agents will be chosen based on the disease, disorder, or condition being treated. In addition to a therapeutic agent for a particular condition, other compounds may be included for secondary effects, for example, an antibiotic to prevent microbial growth. The amount and frequency of the dosage will depend on the disease, disorder, or condition being treated and the therapeutic agent employed. One skilled in the art can make this determination.
Therapeutic agents that may be employed in the device of the invention include, without limitation, small molecules, honnones, proteins, peptides, aptamers, antibodies, lipids, glycolipids, DNA, RNA, PNA, enzymes, sugars, saccharides, glycoproteins, polymers, metalloproteases, transition metals, or chelators. In addition, nucleic acid vectors can also be delivered wherein the nucleic acid may be expressed to produce a protein that may have a variety of pharmacological, physiological or immunological activities.
Macromolecules with a molecular weight of about 5 kDa to about 500 kDa may also be used in accordance with the invention.
For oplithahnic drug delivery applications, exeinplary disease states include macular degeneration, diabetic retinopathy, glaucoma, optic disc neovascularization, iris neovascularization, retinal neovascularization, choroidal neovascularization, pannus, pterygiuin, macular edema, vascular retinopathy, retinal vein occlusion, histoplasmosis, ischemic retinal disease, retinal degeneration, uveitis, inflammatory diseases of the retina, keratitis, cytomegalovirus retinitis, an infection, conjunctivitis, cystoid macular edema, cancer, and proliferative vitreoretinopathy.
Classes of therapeutic agents include anti-infectives including, without limitation, antibiotics, antivirals, and antifungals; analgesics; antiallergenic agents;
mast cell stabilizers;
steroidal and non-steroidal anti-inflammatory agents; decongestants; anti-glaucoma agents including, without limitation, adrenergics, beta-adrenergic blocking agents, alpha-adrenergic blocking agonists, parasyinpathomimetic agents, cholinesterase inhibitors, carbonic anhydrase inlubitors, and protaglandins; antioxidants; nutritional supplements; angiogenesis inhibitors; antimetabolites; fibrinolytics; wound modulating agents;
neuroprotective drugs;
angiostatic steroids; mydriatics; cyclopegic mydriatics; miotics;
vasoconstrictors;
vasodilators; anticlotting agents; anticancer agents; immunomodulatory agents;
VEGF
antagonists; immunosuppresant agents; and combinations and prodrugs thereof.
Specific therapeutic agents include MACUGEN (pegaptanib sodium injection) as described in U.S. Patent No. 6,051,698, herein incorporated in its entirety by reference.
Pegaptanib sodium is also referred to as EYE001 or NX183S.
Pegaptanib sodiuin is a covalent conjugate of an oligonucleotide of twenty-eight nucleotides in length that terminates in a pentylamino linker, to which two 20-kilodalton (kDa) monomethoxypolyethylene glycol (PEG) units are covalently attached via the two amino groups on a lysine residue. The molecular formula for pegaptanib sodium is C294H342F13N107Na28O188P28(CZH4O)õ (where n is approximately 900) and the molecular weight is approximately 50 kDa.
Injections include, but are not limited to, liquid preparations that are drug substances or solutions/suspensions thereof.
By "substantially constant pressure" is meant pressure that is constant with minor, teinporary variations due to filling, emptying, or a change in osmotic pressure of the surrounding liquid.
"Parenteral" articles are preparations intended for injection through the skin or other external boundary tissue, rather than through the alimentary canal, so that the active substances they contain are administered, using gravity or force, directly into a blood vessel, organ, tissue, or lesion. Parenteral articles are prepared by metllods designed to ensure that they meet Pharmacopeial requirements for sterility, pyrogens, particulate matter, and other contaminants (USP Chapter 1).
The designation "Small-Volume Injection" applies to an injection that is packaged in containers labeled as containing 100 mL or less.
The designation "Microliter-volume Injection" or "Ultra-Low-Volume Injection"
applies to an Injection that is packaged in containers labeled as containing 1.0 mL (1000 L) or less.
As used herein, the term "dead space" or "Waste space" is the volume of injection solution within the syringe/needle asseinbly containing any residual injection solution present following an injection that does not get evacuated from the syringe during the injection.
By "therapeutic agent" is meant any compound or mixture of compounds that provide a therapeutic effect for one or more diseases, disorders, or conditions. Such compounds include, without limitation, small organic or inorganic molecules, proteins (e.g., antibodies), peptides, lipids (e.g., steroids) and nucleic acids (e.g., aptamers).
Therapeutic agents are, for example, antibiotics, analgesics, anti-inflammatory compounds, or any other compound for the treatment of a disease, disorder, or condition.
By "treating" is meant the medical management of a patient with the intent that a cure, amelioration, or prevention of a disease, pathological condition, or disorder will result. This tenn includes active treatment, that is, treatinent directed specifically toward improvement of a disease, pathological condition, or disorder, and also includes causal treatment, that is, treatment directed toward removal of the cause of the disease, pathological condition, or disorder. In addition, this tenn includes palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the disease, pathological condition, or disorder;
preventive treatment, that is, treatment directed to prevention of the disease, patliological condition, or disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the disease, pathological condition, or disorder. The term "treating" also includes symptomatic treatment, that is, treatment directed toward constitutional syiuptoms of the disease, pathological condition, or disorder.
Ophthalmic solutions are sterile solutions, essentially free from foreign particles, suitably compounded and packaged for instillation or injection into the eye.
Preparation of an ophthalmic solution requires careful consideration of such factors as the inherent toxicity of the drug itself, isotonicity value, the need for buffering agents, the need for a preservative (and, if needed, its selection), sterilization, and proper packaging.
While specific reference has been made to the use of the devices of the present invention to administer therapeutic agents to the eye, it is to be understood that the present invention can be used to deliver a therapeutic agent to any desired site, including, but not limited to, intraorbital, intraocular, intraaural, intratympanic, intrathecal, intracavitary, peritumoral, intratumoral, intraspinal, epidural, intracranial, and intracardial.
A device of the invention may be used in the treatment of any eye disease. A
device of the invention may also be used to direct a therapeutic agent to a particular eye tissue, e.g., the retina or the choroid. The therapeutic agent or combination of agents will be chosen based on the disease, disorder, or condition being treated. In addition to a therapeutic agent for a particular condition, other compounds may be included for secondary effects, for example, an antibiotic to prevent microbial growth. The amount and frequency of the dosage will depend on the disease, disorder, or condition being treated and the therapeutic agent employed. One skilled in the art can make this determination.
Therapeutic agents that may be employed in the device of the invention include, without limitation, small molecules, honnones, proteins, peptides, aptamers, antibodies, lipids, glycolipids, DNA, RNA, PNA, enzymes, sugars, saccharides, glycoproteins, polymers, metalloproteases, transition metals, or chelators. In addition, nucleic acid vectors can also be delivered wherein the nucleic acid may be expressed to produce a protein that may have a variety of pharmacological, physiological or immunological activities.
Macromolecules with a molecular weight of about 5 kDa to about 500 kDa may also be used in accordance with the invention.
For oplithahnic drug delivery applications, exeinplary disease states include macular degeneration, diabetic retinopathy, glaucoma, optic disc neovascularization, iris neovascularization, retinal neovascularization, choroidal neovascularization, pannus, pterygiuin, macular edema, vascular retinopathy, retinal vein occlusion, histoplasmosis, ischemic retinal disease, retinal degeneration, uveitis, inflammatory diseases of the retina, keratitis, cytomegalovirus retinitis, an infection, conjunctivitis, cystoid macular edema, cancer, and proliferative vitreoretinopathy.
Classes of therapeutic agents include anti-infectives including, without limitation, antibiotics, antivirals, and antifungals; analgesics; antiallergenic agents;
mast cell stabilizers;
steroidal and non-steroidal anti-inflammatory agents; decongestants; anti-glaucoma agents including, without limitation, adrenergics, beta-adrenergic blocking agents, alpha-adrenergic blocking agonists, parasyinpathomimetic agents, cholinesterase inhibitors, carbonic anhydrase inlubitors, and protaglandins; antioxidants; nutritional supplements; angiogenesis inhibitors; antimetabolites; fibrinolytics; wound modulating agents;
neuroprotective drugs;
angiostatic steroids; mydriatics; cyclopegic mydriatics; miotics;
vasoconstrictors;
vasodilators; anticlotting agents; anticancer agents; immunomodulatory agents;
VEGF
antagonists; immunosuppresant agents; and combinations and prodrugs thereof.
Specific therapeutic agents include MACUGEN (pegaptanib sodium injection) as described in U.S. Patent No. 6,051,698, herein incorporated in its entirety by reference.
Pegaptanib sodium is also referred to as EYE001 or NX183S.
Pegaptanib sodiuin is a covalent conjugate of an oligonucleotide of twenty-eight nucleotides in length that terminates in a pentylamino linker, to which two 20-kilodalton (kDa) monomethoxypolyethylene glycol (PEG) units are covalently attached via the two amino groups on a lysine residue. The molecular formula for pegaptanib sodium is C294H342F13N107Na28O188P28(CZH4O)õ (where n is approximately 900) and the molecular weight is approximately 50 kDa.
The chemical name for pegaptanib sodium is as follows: RNA, ((2'-deoxy-2'-fluoro)C-G,,; G,,; AA-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)C-A,,; G,n (2'-deoxy-2' -fluoro)U-G,n Ap A,,; (2'-deoxy-2'-fluoro)U-G,n (2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)U-A,ri (2'-deoxy-2'-fluoro)U-A,n (2'-deoxy-2'-fluoro)C-A,n (2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)C-G,n (3'-->3')-dT), 5'-ester with a, a'-[4,12-dioxo-6- [[ [5-(phosphoonoxy)p entyl] amino] carbonyl]-3,13-dioxa-5,11-diaza-1,15-pentadecanediyl]bis[co-methoxypoly(oxy-1,2-ethanediyl)], sodium salt.
MACUGEN (pegaptanib sodium injection) is a sterile, aqueous solution containing pegaptanib sodium for intravitreous injection. Macugen is supplied in a single-dose, pre-filled syringe and is formulated as a 3.47 mg/mL solution, measured as the free acid form of the oligonucleotide. The active ingredient is 0.3 mg of the free acid form of the oligonucleotide without polyethylene glycol, in a nominal volume of 90 L.
This dose is equivalent to 1.6 mg of pegaptanib sodium (PEGylated oligonucleotide) or 0.32 mg when expressed as the sodium salt form of the oligonucleotide moiety. The product is a sterile, clear, preservative-free solution containing sodium chloride, monobasic sodium phosphate monohydrate, dibasic sodiuin phosphate heptahydrate, hydrochloric acid, and/or sodium hydroxide to adjust the pH and water for injection. Macugen is formulated to have an osmolality of 280-360 mOsn1/Kg, and a pH of 6-7.
Dosage levels of pegaptanib sodium on the order of about 1 gg/kg to 100 mg/kg of body weight per administration are useful in the treatment of neovascular disorders.
Examples of formulations are found in WO 03/039404, which is hereby incorporated by reference in its entirety. In some embodiments, pegaptanib sodium is administered at a dosage of about 0.1 mg to about 1.0 mg locally into the eye, wherein the treatment is effective to treat occult, minimally classic, and predominantly classic forms of wet macular degeneration. When administered directly to the eye, the dosage range is about 0.3 mg to about 3 mg per eye, in some embodiments the dosage range is about 0.1 mg to about 1.0 mg per eye. In one embodiment, pegaptanib sodium is administered in a therapeutically effective amount of about 0.003 - 3.0 mg, 0.1 - 1.0 mg, or about 0.3 mg. In one embodiment, pegaptanib sodium is present in an ophthalmic injection solution fonnulation at a concentration ranging from 0.003 to 3.0 mg/mL. According to one embodiment, the carrier comprises sodium phosphate and sodium chloride. According to one specific embodiment the carrier comprises 10 mM sodium phosphate and 0.9% sodium chloride.
According to one embodiment, the dose is effective to achieve a vitreous concentration of the anti-VEGF aptamer of about 10-30 ng/mL. According to another embodiinent, the dose is effective to maintain a vitreous concentration of the anti-VEGF
aptamer of about 10-30 nghnL throughout a 6 week dosing interval.
5 In alternative embodiments, the anti-VEGF agent is an anti-VEGF aptamer and is administered at a dosage of less than 0.3 mg to about 0.003 mg locally into the eye. In some embodiments, the anti-VEGF aptamer is administered at a dosage less than about 0.30 mg.
Examples of such formulations are found in US Patent Application Serial No.
60/692,727;
which is hereby incorporated by reference in its entirety.
10 Specific therapeutic agents also include the anti-PDGF aptamer ARC-127 (Archemix Corp., Cainbridge, MA), a PEGylated, anti-PDGF aptamer having the sequence CAGGCUACGN CGTAGAGCAU CANTGATCCU GT (SEQ ID NO: 10 from U.S. Patent No. 6,582,918, incorporated herein by reference in its entirety) having 2'-fluoro-2'-deoxyuridine at positions 6, 20 and 30, 2'-fluoro-2'-deoxycytidine at positions 8, 21, 28, and 15 29, 2'-O-Methyl-2'-deoxyguanosine at positions 9, 15, 17, and 31, 2'-O-Methyl-2'-deoxyadenosine at position 22, hexaethylene-glycol phosphoramidite at "N" in positions 10 and 23, and an inverted orientation T (i.e., 3'-3'-linked) at position 32.
A combination therapy for the treatment of ocular neovascular disorders using a VEGF antagonist and a PDGF antagonist is described in PCT Application 20 No. WO 2005/020972, whicll is incorporated herein by reference in its entirety. An example of such a therapy comprises the administration of a coinbination of Macugen and ARC127.
According to another embodiment, the present invention features a method for treating a patient suffering from an ocular disease, which method includes the following steps: (a) administering to the patient an effective amount of an anti- VEGF
aptamer; and (b) providing the patient with phototherapy, such as photodynainic tllerapy or thermal laser photocoagulation as further described in PCT WO 03/039404, incorporated in its entirety by reference.
In one embodiment of the invention, the photodynamic therapy (PDT) includes the steps of: (i) delivering a photosensitizer to the eye tissue of a patient; and (ii) exposing the photosensitizer to light having a wavelength absorbed by the photosensitizer for a time and at an intensity sufficient to inhibit neovascularization in the patient's eye tissue. A variety of pllotosensitizers may be used, including but not limited to, benzoporphyrin derivatives (BPD), monoaspartyl chlorine, zinc phthalocyanine, tin etiopurpurin, tetrahydroxy tetraphenylporphyrin, and porfimer sodium (PHOTOFRIN), and green porphyrins.
Other therapeutic agents include 4,9(11)-pregnadien-17a,21-diol-3,20-dione, 4,9(I 1)-pregnadien-17a,21-dio1-3,20-dione-21-acetate, coinbretastatin, timolol, betaxolol, atenolol, brimonidine, acetazolamide, methazolamide, dichlorphenamide, diamox, nimodipine, eliprodil, colchicine, vincristine, cytochalasin B, tetracycline, chlortetracycline, bacitracin, neomycin, polymyxin, gramicidin, oxytetracycline, chlorainphenicol, gentamycin, erythromycin, sulfonamides, sulfacetainide, sulfamethizole, sulfisoxazole, fluconazole, nitrofurazone, amphotericin B, ketoconazole, trifluorothymidine, acyclovir, ganciclovir, didanosine, AZT, foscainet, vidarabine, idoxuridine, ribavirin, protease inhibitors, anti-cytomegalovirus agents, methapyriline; chlorpheniramine, pyrilamine pheniramine, hydrocortisone, dexamethasone, fluocinolone, prednisone, prednisolone, methylprednisolone, fluorometholone, betamethasone, triaincinolone, phenylephrine, naphazoline, tetrallydrozoline, pilocarpine, carbachol, diisopropylfluorophosphate, echothiophate iodide, demecarium bromide, atropine sulfate, cyclopentolate, homatropine, scopolamine, tropicamide, eucatropine, epinephrine, heparin, antifibrinogen, fibrinolysin, anti clotting activase, acetohexamide, chlorpropamide, glipizide, glyburide, tolazamide, tolbutamide, insulin, aldose reductase inhibitors, thalidomide, folic acid, 5-fluorouracil, adriamycin, asparaginase, azacytidine, azathioprine, bleomycin, busulfan, carboplatin, cannustine, chlorambucil, cisplatin, cyclophosphamide, cyclosporine, cytarabine, dacarbazine, dactinomycin, daunorubicin, estramustine, etoposide, etretinate, filgrastim, floxuridine, fludarabine, fluoxymesterone, flutamide, goserelin, hydroxyurea, ifosfamide, leuprolide, levamisole, lomustine, nitrogen mustard, melphalan, mercaptopurine, methotrexate, ,25 mitomycin, mitotane, pentostatin, pipobroman, plicamycin, procarbazine, sargramostim, streptozocin, tamoxifen, taxol, teniposide, thioguanine, uracil mustard, vinblastine, vindesine, pituitary hormones, , insulin-related growth factor, thyroid hormones, growth horinones, heat shock proteins, iinmunological response modifiers such as muramyl dipeptide, interferons (including a, 0, and y interferons), interleukin-2, cytokines; FK506, tumor necrosis factor, thymopentin, transforming factor beta2, erythropoietin; antineogenesis proteins, monoclonal antibodies, brain neive growth factor (BNGF), celiary nerve growth factor (CNGF), vascular endothelial growth factor (VEGF), monoclonal antibodies or aptamers directed against growth factors, and combinations and prodrugs thereof:
MACUGEN (pegaptanib sodium injection) is a sterile, aqueous solution containing pegaptanib sodium for intravitreous injection. Macugen is supplied in a single-dose, pre-filled syringe and is formulated as a 3.47 mg/mL solution, measured as the free acid form of the oligonucleotide. The active ingredient is 0.3 mg of the free acid form of the oligonucleotide without polyethylene glycol, in a nominal volume of 90 L.
This dose is equivalent to 1.6 mg of pegaptanib sodium (PEGylated oligonucleotide) or 0.32 mg when expressed as the sodium salt form of the oligonucleotide moiety. The product is a sterile, clear, preservative-free solution containing sodium chloride, monobasic sodium phosphate monohydrate, dibasic sodiuin phosphate heptahydrate, hydrochloric acid, and/or sodium hydroxide to adjust the pH and water for injection. Macugen is formulated to have an osmolality of 280-360 mOsn1/Kg, and a pH of 6-7.
Dosage levels of pegaptanib sodium on the order of about 1 gg/kg to 100 mg/kg of body weight per administration are useful in the treatment of neovascular disorders.
Examples of formulations are found in WO 03/039404, which is hereby incorporated by reference in its entirety. In some embodiments, pegaptanib sodium is administered at a dosage of about 0.1 mg to about 1.0 mg locally into the eye, wherein the treatment is effective to treat occult, minimally classic, and predominantly classic forms of wet macular degeneration. When administered directly to the eye, the dosage range is about 0.3 mg to about 3 mg per eye, in some embodiments the dosage range is about 0.1 mg to about 1.0 mg per eye. In one embodiment, pegaptanib sodium is administered in a therapeutically effective amount of about 0.003 - 3.0 mg, 0.1 - 1.0 mg, or about 0.3 mg. In one embodiment, pegaptanib sodium is present in an ophthalmic injection solution fonnulation at a concentration ranging from 0.003 to 3.0 mg/mL. According to one embodiment, the carrier comprises sodium phosphate and sodium chloride. According to one specific embodiment the carrier comprises 10 mM sodium phosphate and 0.9% sodium chloride.
According to one embodiment, the dose is effective to achieve a vitreous concentration of the anti-VEGF aptamer of about 10-30 ng/mL. According to another embodiinent, the dose is effective to maintain a vitreous concentration of the anti-VEGF
aptamer of about 10-30 nghnL throughout a 6 week dosing interval.
5 In alternative embodiments, the anti-VEGF agent is an anti-VEGF aptamer and is administered at a dosage of less than 0.3 mg to about 0.003 mg locally into the eye. In some embodiments, the anti-VEGF aptamer is administered at a dosage less than about 0.30 mg.
Examples of such formulations are found in US Patent Application Serial No.
60/692,727;
which is hereby incorporated by reference in its entirety.
10 Specific therapeutic agents also include the anti-PDGF aptamer ARC-127 (Archemix Corp., Cainbridge, MA), a PEGylated, anti-PDGF aptamer having the sequence CAGGCUACGN CGTAGAGCAU CANTGATCCU GT (SEQ ID NO: 10 from U.S. Patent No. 6,582,918, incorporated herein by reference in its entirety) having 2'-fluoro-2'-deoxyuridine at positions 6, 20 and 30, 2'-fluoro-2'-deoxycytidine at positions 8, 21, 28, and 15 29, 2'-O-Methyl-2'-deoxyguanosine at positions 9, 15, 17, and 31, 2'-O-Methyl-2'-deoxyadenosine at position 22, hexaethylene-glycol phosphoramidite at "N" in positions 10 and 23, and an inverted orientation T (i.e., 3'-3'-linked) at position 32.
A combination therapy for the treatment of ocular neovascular disorders using a VEGF antagonist and a PDGF antagonist is described in PCT Application 20 No. WO 2005/020972, whicll is incorporated herein by reference in its entirety. An example of such a therapy comprises the administration of a coinbination of Macugen and ARC127.
According to another embodiment, the present invention features a method for treating a patient suffering from an ocular disease, which method includes the following steps: (a) administering to the patient an effective amount of an anti- VEGF
aptamer; and (b) providing the patient with phototherapy, such as photodynainic tllerapy or thermal laser photocoagulation as further described in PCT WO 03/039404, incorporated in its entirety by reference.
In one embodiment of the invention, the photodynamic therapy (PDT) includes the steps of: (i) delivering a photosensitizer to the eye tissue of a patient; and (ii) exposing the photosensitizer to light having a wavelength absorbed by the photosensitizer for a time and at an intensity sufficient to inhibit neovascularization in the patient's eye tissue. A variety of pllotosensitizers may be used, including but not limited to, benzoporphyrin derivatives (BPD), monoaspartyl chlorine, zinc phthalocyanine, tin etiopurpurin, tetrahydroxy tetraphenylporphyrin, and porfimer sodium (PHOTOFRIN), and green porphyrins.
Other therapeutic agents include 4,9(11)-pregnadien-17a,21-diol-3,20-dione, 4,9(I 1)-pregnadien-17a,21-dio1-3,20-dione-21-acetate, coinbretastatin, timolol, betaxolol, atenolol, brimonidine, acetazolamide, methazolamide, dichlorphenamide, diamox, nimodipine, eliprodil, colchicine, vincristine, cytochalasin B, tetracycline, chlortetracycline, bacitracin, neomycin, polymyxin, gramicidin, oxytetracycline, chlorainphenicol, gentamycin, erythromycin, sulfonamides, sulfacetainide, sulfamethizole, sulfisoxazole, fluconazole, nitrofurazone, amphotericin B, ketoconazole, trifluorothymidine, acyclovir, ganciclovir, didanosine, AZT, foscainet, vidarabine, idoxuridine, ribavirin, protease inhibitors, anti-cytomegalovirus agents, methapyriline; chlorpheniramine, pyrilamine pheniramine, hydrocortisone, dexamethasone, fluocinolone, prednisone, prednisolone, methylprednisolone, fluorometholone, betamethasone, triaincinolone, phenylephrine, naphazoline, tetrallydrozoline, pilocarpine, carbachol, diisopropylfluorophosphate, echothiophate iodide, demecarium bromide, atropine sulfate, cyclopentolate, homatropine, scopolamine, tropicamide, eucatropine, epinephrine, heparin, antifibrinogen, fibrinolysin, anti clotting activase, acetohexamide, chlorpropamide, glipizide, glyburide, tolazamide, tolbutamide, insulin, aldose reductase inhibitors, thalidomide, folic acid, 5-fluorouracil, adriamycin, asparaginase, azacytidine, azathioprine, bleomycin, busulfan, carboplatin, cannustine, chlorambucil, cisplatin, cyclophosphamide, cyclosporine, cytarabine, dacarbazine, dactinomycin, daunorubicin, estramustine, etoposide, etretinate, filgrastim, floxuridine, fludarabine, fluoxymesterone, flutamide, goserelin, hydroxyurea, ifosfamide, leuprolide, levamisole, lomustine, nitrogen mustard, melphalan, mercaptopurine, methotrexate, ,25 mitomycin, mitotane, pentostatin, pipobroman, plicamycin, procarbazine, sargramostim, streptozocin, tamoxifen, taxol, teniposide, thioguanine, uracil mustard, vinblastine, vindesine, pituitary hormones, , insulin-related growth factor, thyroid hormones, growth horinones, heat shock proteins, iinmunological response modifiers such as muramyl dipeptide, interferons (including a, 0, and y interferons), interleukin-2, cytokines; FK506, tumor necrosis factor, thymopentin, transforming factor beta2, erythropoietin; antineogenesis proteins, monoclonal antibodies, brain neive growth factor (BNGF), celiary nerve growth factor (CNGF), vascular endothelial growth factor (VEGF), monoclonal antibodies or aptamers directed against growth factors, and combinations and prodrugs thereof:
A therapeutic agent may be present in any suitable formulation for delivery to the eye.
Methods well known in the art for making formulations are found, for example, in Renaington: Th.e Science and Practice of Pharmacy (20th ed., A.R. Gennaro ed., Lippincott:
Philadelphia, 2000). Therapeutic agents may be administered to humans, domestic pets, livestock, or other animals with a pharmaceutically acceptable diluent, carrier, or excipient.
Therapeutic formulations may be liquid solutions, suspensions, or other formulations deliverable via a needle. Formulations may, for exainple, contain excipients, sterile water, saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or hydrogenated napthalenes.
The therapeutic agent may be admixed witll a pharmaceutically acceptable carrier adapted to provide sustained release of the therapeutic agent. Sustained release carriers include emulsions, suspensions, polymeric matrices, microspheres, microcapsules, microparticles, liposomes, multivesicular liposomes, lipospheres, hydrogels, salts, and polymers with the therapeutic agent reversibly bound electrostatically, chemically or by entrapment. Suitable sustained release forinulations which may be used are known in the art and are disclosed in, for example, U.S. Patent Nos. 4,865,846, 4,115,544, 5,185,152, 4,078,052, 4,241,046, 4,853,224, 4,865,846, 6,309,669, 5,326,761, 6,071,534, 6,132,766 and 6,277,413 and PCTs WO 01/74400, WO 03/24420, WO 03/028765, WO 02/15888, WO
03/092665 and WO 03/070219, all of which are hereby incorporated in their entirety by reference.
Formulations of the drug may also include a transscleral diffusion promoting agent, such as dimethylsulfoxide, ethanol, dimethylformamide, propylene glycol, N-methylpyrolidone, oleic acid, isopropyl myristate, polar aprotic solvents, polar protic solvents, steroids, sugars, polymers, small molecules, charged small molecules, lipids, peptides, proteins, and surfactants.
A therapeutic agent may be optionally administered as a pharmaceutically acceptable salt, such as a non-toxic acid addition salts or metal complexes that are commonly used in the pharmaceutical industry. Examples of acid addition salts include organic acids such as acetic, lactic, pamoic, maleic, citric, malic, ascorbic, succinic, benzoic, palmitic, suberic, salicylic, tartaric, methanesulfonic, toluenesulfonic, or trifluoroacetic acids or the like; polymeric acids such as tannic acid, carboxymethyl cellulose, or the like; and inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, or the like. Metal complexes include cations, such as divalent cations including calcium and magnesium, zinc, iron, and the like. In addition, a therapeutic agent may be optionally administered as a phannaceutically acceptable prodrug, e.g., an ester or amide.
The chemical compounds for use in such therapies may be produced and isolated as described herein or by any standard technique known to those in the field of medicinal chemistry. Conventional pharmaceutical practice may be employed to provide suitable formulations or compositions to administer the identified compound to patients suffering from a disease, disorder, or condition of the eye.
Administration may begin before, during, or after the patient is symptomatic.
Although the above process was described using the syringe of the invention, alternative methods of injection can be employed. Other variations on these configurations will be apparent to one skilled in the art.
EXAMPLES
The following examples serve to illustrate certain usefal embodiments and aspects of the present invention and are not to be construed as limiting the scope thereof. Alternative materials and methods can be utilized to obtain similar results.
Example 1 Macugen Formulation Macugen ((OSI) Eyetech, Inc., NY, NY) is formulated at 0.3mg/90 L having a tungsten particulate count of less than 150 ppb. The solution is presented in USP Type I
glass barrel syringes fitted with a Luer lock hub and sealed with a bromobutyl rubber plunger stopper. The syringe is fitted with a Luer lock 27-gauge, multi-beveled, silicone coated needle with a rigid plastic outer shield. The needle requires a penetration force of less than 100 g.
Methods well known in the art for making formulations are found, for example, in Renaington: Th.e Science and Practice of Pharmacy (20th ed., A.R. Gennaro ed., Lippincott:
Philadelphia, 2000). Therapeutic agents may be administered to humans, domestic pets, livestock, or other animals with a pharmaceutically acceptable diluent, carrier, or excipient.
Therapeutic formulations may be liquid solutions, suspensions, or other formulations deliverable via a needle. Formulations may, for exainple, contain excipients, sterile water, saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or hydrogenated napthalenes.
The therapeutic agent may be admixed witll a pharmaceutically acceptable carrier adapted to provide sustained release of the therapeutic agent. Sustained release carriers include emulsions, suspensions, polymeric matrices, microspheres, microcapsules, microparticles, liposomes, multivesicular liposomes, lipospheres, hydrogels, salts, and polymers with the therapeutic agent reversibly bound electrostatically, chemically or by entrapment. Suitable sustained release forinulations which may be used are known in the art and are disclosed in, for example, U.S. Patent Nos. 4,865,846, 4,115,544, 5,185,152, 4,078,052, 4,241,046, 4,853,224, 4,865,846, 6,309,669, 5,326,761, 6,071,534, 6,132,766 and 6,277,413 and PCTs WO 01/74400, WO 03/24420, WO 03/028765, WO 02/15888, WO
03/092665 and WO 03/070219, all of which are hereby incorporated in their entirety by reference.
Formulations of the drug may also include a transscleral diffusion promoting agent, such as dimethylsulfoxide, ethanol, dimethylformamide, propylene glycol, N-methylpyrolidone, oleic acid, isopropyl myristate, polar aprotic solvents, polar protic solvents, steroids, sugars, polymers, small molecules, charged small molecules, lipids, peptides, proteins, and surfactants.
A therapeutic agent may be optionally administered as a pharmaceutically acceptable salt, such as a non-toxic acid addition salts or metal complexes that are commonly used in the pharmaceutical industry. Examples of acid addition salts include organic acids such as acetic, lactic, pamoic, maleic, citric, malic, ascorbic, succinic, benzoic, palmitic, suberic, salicylic, tartaric, methanesulfonic, toluenesulfonic, or trifluoroacetic acids or the like; polymeric acids such as tannic acid, carboxymethyl cellulose, or the like; and inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, or the like. Metal complexes include cations, such as divalent cations including calcium and magnesium, zinc, iron, and the like. In addition, a therapeutic agent may be optionally administered as a phannaceutically acceptable prodrug, e.g., an ester or amide.
The chemical compounds for use in such therapies may be produced and isolated as described herein or by any standard technique known to those in the field of medicinal chemistry. Conventional pharmaceutical practice may be employed to provide suitable formulations or compositions to administer the identified compound to patients suffering from a disease, disorder, or condition of the eye.
Administration may begin before, during, or after the patient is symptomatic.
Although the above process was described using the syringe of the invention, alternative methods of injection can be employed. Other variations on these configurations will be apparent to one skilled in the art.
EXAMPLES
The following examples serve to illustrate certain usefal embodiments and aspects of the present invention and are not to be construed as limiting the scope thereof. Alternative materials and methods can be utilized to obtain similar results.
Example 1 Macugen Formulation Macugen ((OSI) Eyetech, Inc., NY, NY) is formulated at 0.3mg/90 L having a tungsten particulate count of less than 150 ppb. The solution is presented in USP Type I
glass barrel syringes fitted with a Luer lock hub and sealed with a bromobutyl rubber plunger stopper. The syringe is fitted with a Luer lock 27-gauge, multi-beveled, silicone coated needle with a rigid plastic outer shield. The needle requires a penetration force of less than 100 g.
Example 2 Macugen0 Formulation Macugen (Eyetech Pharmaceuticals, NY, NY) is fonnulated at 0.3mg/90 L, 0.031ng/90 L or 0.003mg/90 L and presented in USP Type I glass barrel syringes sealed with a bromobutyl rubber plunger stopper. The syringe is fitted with a Luer lock 27-gauge needle with a rigid plastic outer shield. The stoppered syringe is packaged in a foil pouch. A
plastic plunger rod and flange adapter are also supplied for administration purposes. These components are provided in a separate foil pouch. Use of the flange is optional and is not required to administer the injection. The drug product is preservative-free and intended for single use by intravitreous injection only. The product should not be used if cloudy or if particles are present.
Active Ingredient: Pegaptanib Sodium Injection formulated as:
= 0.0347mg/mL solution to deliver a dose of 0.003mg pegaptanib sodium injection = 0.347mg/mL solution to deliver a dose of 0.03mg pegaptanib sodium injection = 3.47mg/mL solution to deliver a dose of 0.3mg pegaptanib sodium injection Excipients: Sodium Chloride, USP
Sodium Phosphate Monobasic, Monohydrate, USP
Sodium Phosphate Dibasic, Heptahydrate, USP
Sodium Hydroxide, USP (as needed) Hydrochloric acid, USP (as needed) Water for injection, USP
Preparation The drug product pegaptanib sodium is a ready-to-use sterile solution provided in a single-use glass syringe. Administration of the syringe contents involves attaching the threaded plastic plunger rod to the rubber stopper inside the barrel of the syringe. The rubber end cap is then reinoved to allow administration of the product. An optional flange is provided for adininistrative purposes.
5 Example 3 Intravitreous Injection 1% Mydriacyl and 2.5% Phenylephrine are applied topically to the study eye to achieve adequate pupillary dilation. Two to three drops of 50% saline diluted 10% povidone-iodine (betadine) solution are instilled into the eye. In the event of allergy to iodine, a drop of 10 topical antibiotic is placed on the conjunctiva in place of iodine. A
subconjunctival injection of 0.5 m12% xylocaine without epinephrine is administered in the inferotemporal quadrant in all patients - 3.0 to 3.5 inm from the limbus in aphakic/pseudophakic patients, and 3.5 to 4.0 mm in phakic patients. Investigators are instructed to select one of two pre-injection procedures (Options A and B, below). For patients witll iodine allergy, investigators are 15 required follow Option A, instilling one additional drop of antibiotic instead of povidone-iodine.
A. Adininister topical ofloxacin, levofloxacin, or an antibiotic drop with comparable antimicrobial coverage for three days prior to the treatment followed by three consecutive drops of antibiotic and several drops of 5% povidone-iodine iminediately 20 before the treatment B. Administer three consecutive drops of antibiotic and a 5% povidone-iodine flush of the fornices and caruncle with at least 10 cc of solution just prior to treatinent.
Prior to treatment, topical antibiotic drops are administered 3 times separated by at least 5 minutes within one hour prior to treatment.
plastic plunger rod and flange adapter are also supplied for administration purposes. These components are provided in a separate foil pouch. Use of the flange is optional and is not required to administer the injection. The drug product is preservative-free and intended for single use by intravitreous injection only. The product should not be used if cloudy or if particles are present.
Active Ingredient: Pegaptanib Sodium Injection formulated as:
= 0.0347mg/mL solution to deliver a dose of 0.003mg pegaptanib sodium injection = 0.347mg/mL solution to deliver a dose of 0.03mg pegaptanib sodium injection = 3.47mg/mL solution to deliver a dose of 0.3mg pegaptanib sodium injection Excipients: Sodium Chloride, USP
Sodium Phosphate Monobasic, Monohydrate, USP
Sodium Phosphate Dibasic, Heptahydrate, USP
Sodium Hydroxide, USP (as needed) Hydrochloric acid, USP (as needed) Water for injection, USP
Preparation The drug product pegaptanib sodium is a ready-to-use sterile solution provided in a single-use glass syringe. Administration of the syringe contents involves attaching the threaded plastic plunger rod to the rubber stopper inside the barrel of the syringe. The rubber end cap is then reinoved to allow administration of the product. An optional flange is provided for adininistrative purposes.
5 Example 3 Intravitreous Injection 1% Mydriacyl and 2.5% Phenylephrine are applied topically to the study eye to achieve adequate pupillary dilation. Two to three drops of 50% saline diluted 10% povidone-iodine (betadine) solution are instilled into the eye. In the event of allergy to iodine, a drop of 10 topical antibiotic is placed on the conjunctiva in place of iodine. A
subconjunctival injection of 0.5 m12% xylocaine without epinephrine is administered in the inferotemporal quadrant in all patients - 3.0 to 3.5 inm from the limbus in aphakic/pseudophakic patients, and 3.5 to 4.0 mm in phakic patients. Investigators are instructed to select one of two pre-injection procedures (Options A and B, below). For patients witll iodine allergy, investigators are 15 required follow Option A, instilling one additional drop of antibiotic instead of povidone-iodine.
A. Adininister topical ofloxacin, levofloxacin, or an antibiotic drop with comparable antimicrobial coverage for three days prior to the treatment followed by three consecutive drops of antibiotic and several drops of 5% povidone-iodine iminediately 20 before the treatment B. Administer three consecutive drops of antibiotic and a 5% povidone-iodine flush of the fornices and caruncle with at least 10 cc of solution just prior to treatinent.
Prior to treatment, topical antibiotic drops are administered 3 times separated by at least 5 minutes within one hour prior to treatment.
25 For patients who are prepared under Option A, following the last dose of antibiotic, the investigator instills two or three drops of 5% povidone-iodine into the eye. Using sterile gloves and cotton-tip applicators soaked in 5% povidone iodine, the investigator scrubs the eyelids, the upper and lower eyelid margins, and the caruncle 3 times. In the event of allergy to iodine, one additional drop of antibiotic is instilled instead of povidone-iodine.
For patients who are prepared under Option B, the investigator waits at least minutes after the last dose of antibiotic to perform a 5% povidone-iodine flush, irrigating the fornices and the caruncle with at least 10 cc of 5% povidone-iodine using a forced stream from a syringe connected to an angio-catheter to effect mechanical debridement.
After changing gloves, the investigator isolates the ocular field with a drape, pinning the eyelashes to the eyelids, and places one or two drops of 5% povidone-iodine on the ocular surface at the intended treatment site. An eyelid speculum is used for all injections.
Example 4 Needle Penetration of Porcine Sclera Data was recorded on a Universal Material Testing Machine (Instron Corporation, Norwood, MA) to mimic insertion of the needle into the eye 6 inm below the sclera. The data was then transferred to a MINITAB statistical software (Minitab, Inc, State College, PA) for analysis.
The sainples (n=15) were tested as follows:
Control: Becton Dickenson (BD) 1 cc TB syringe paired with a 27Ga 1/2 inch PrecisionGlideTM needle.
Group 1: HYPAK 1 mL long syringe 27Ga five-bevel %2 inch needle Group 2: HYPAK 1 mL long syringe 29Ga five-bevel %2 inch needle Group 3: BD 1mL TB syringe paired with a 30Ga %Z inch precision glide needle A porcine eye is fixed in test stand and pressurized to standard conditions for blade tests to simulate live conditions. The syringe is placed in the test position on the Instron device. The crosshead speed is set to 150 millimeters per minute. The needle is penetrated about %2 the way into the sclera. The penetration location is about 6 inm below the center of the eye pointing toward the center axis of the eye. A new eye is used for each test (60 eyes total). The penetration force resulting from various needles are shown in Table 2 and Figure 8.
After changing gloves, the investigator isolates the ocular field with a drape, pinning the eyelashes to the eyelids, and places one or two drops of 5% povidone-iodine on the ocular surface at the intended treatment site. An eyelid speculum is used for all injections.
Example 4 Needle Penetration of Porcine Sclera Data was recorded on a Universal Material Testing Machine (Instron Corporation, Norwood, MA) to mimic insertion of the needle into the eye 6 inm below the sclera. The data was then transferred to a MINITAB statistical software (Minitab, Inc, State College, PA) for analysis.
The sainples (n=15) were tested as follows:
Control: Becton Dickenson (BD) 1 cc TB syringe paired with a 27Ga 1/2 inch PrecisionGlideTM needle.
Group 1: HYPAK 1 mL long syringe 27Ga five-bevel %2 inch needle Group 2: HYPAK 1 mL long syringe 29Ga five-bevel %2 inch needle Group 3: BD 1mL TB syringe paired with a 30Ga %Z inch precision glide needle A porcine eye is fixed in test stand and pressurized to standard conditions for blade tests to simulate live conditions. The syringe is placed in the test position on the Instron device. The crosshead speed is set to 150 millimeters per minute. The needle is penetrated about %2 the way into the sclera. The penetration location is about 6 inm below the center of the eye pointing toward the center axis of the eye. A new eye is used for each test (60 eyes total). The penetration force resulting from various needles are shown in Table 2 and Figure 8.
Table 2.
Needle Mean penetration Mean Std Dev. Range(grams) force (normalized to Force PrecisionGlide 27G) (grams) PrecisionGlide 27G 1 68.01 19.67 32.93 - 104.10 PrecisionGlide 30G 0.88 59.96 22.92 23.26 - 119.48 HYPAK 27G 2.80 190.3 53.5 113.4 - 318.1 HYPAK 29G Ph siolis 3.24 220.25 61.9 138.8 - 323.3 Incorporation by Reference The patent and scientific literature referred to herein establishes knowledge that is available to those of skill in the art. All patents, patent applications, and published references cited herein are hereby incorporated by reference in their entirety.
Equivalents Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific embodiments described specifically herein. Such equivalents are intended to be encoinpassed in the scope of the following claims.
Needle Mean penetration Mean Std Dev. Range(grams) force (normalized to Force PrecisionGlide 27G) (grams) PrecisionGlide 27G 1 68.01 19.67 32.93 - 104.10 PrecisionGlide 30G 0.88 59.96 22.92 23.26 - 119.48 HYPAK 27G 2.80 190.3 53.5 113.4 - 318.1 HYPAK 29G Ph siolis 3.24 220.25 61.9 138.8 - 323.3 Incorporation by Reference The patent and scientific literature referred to herein establishes knowledge that is available to those of skill in the art. All patents, patent applications, and published references cited herein are hereby incorporated by reference in their entirety.
Equivalents Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific embodiments described specifically herein. Such equivalents are intended to be encoinpassed in the scope of the following claims.
Claims (50)
1. An apparatus for intravitreal injection comprising:
a syringe comprising a barrel having a proximal and a distal end and a volume of 1 mL or less, said barrel adapted to contain an injection solution wherein said solution contains a sub-visible particulate count of less than 50 particles per mL when contained in the barrel;
a Luer lock tip attached to the distal end of the barrel;
a needle having a gauge of 27 or narrower, said needle comprising a cannula attached to a Luer lock hub for attachment to the Luer lock tip, wherein the needle requires a penetration force of less than 100 g to penetrate scleral tissue;
a syringe tip cap attached to the Luer lock tip for sealing a solution contained in the barrel; and a needle tip shield adapted to attach to the Luer lock hub and enclose the needle.
a syringe comprising a barrel having a proximal and a distal end and a volume of 1 mL or less, said barrel adapted to contain an injection solution wherein said solution contains a sub-visible particulate count of less than 50 particles per mL when contained in the barrel;
a Luer lock tip attached to the distal end of the barrel;
a needle having a gauge of 27 or narrower, said needle comprising a cannula attached to a Luer lock hub for attachment to the Luer lock tip, wherein the needle requires a penetration force of less than 100 g to penetrate scleral tissue;
a syringe tip cap attached to the Luer lock tip for sealing a solution contained in the barrel; and a needle tip shield adapted to attach to the Luer lock hub and enclose the needle.
2. The apparatus of claim 1, wherein the needle has a gauge of 29 or narrower.
3. The apparatus of claim 1, wherein the needle is a 30 gauge cannula.
4. The apparatus of claim 1, wherein the needle comprises a multi-bevel tip.
5. The apparatus of claim 1, wherein the needle comprises a 3-bevel tip.
6. The apparatus of claim 1, wherein the needle comprises a 5-bevel tip.
7. The apparatus of claim 1, wherein the needle comprises a silicon coating.
8. The apparatus of claim 1, wherein the needle requires a penetration force of less than 70 g to penetrate scleral tissue.
9. The apparatus of claim 1, wherein the needle requires a penetration force of less than 50 g to penetrate scleral tissue.
10. The apparatus of claim 8, wherein the needle requires a penetration force having a variability of +/- 50 %.
11. The apparatus of claim 8, wherein the needle requires a penetration force having a variability of +/- 30 %.
12. The apparatus of claim 8, wherein the needle requires a penetration force having a variability of +/- 10 %.
13. The apparatus of claim 1, wherein the injection solution contained in the barrel comprises a 10µm-size or larger sub-visible particulate count of less than or equal to 60 particles per mL.
14. The apparatus of claim 1, wherein the injection solution contained in the barrel comprises a 25.µm-size or larger sub-visible particulate count of less than or equal to particles per mL.
15. The apparatus of claim 1, wherein the injection solution contained in the barrel comprises a 50µm-size or larger sub-visible particulate count of less than or equal to 5 particles per mL.
16. The apparatus of claim 1, wherein the injection solution contained in the barrel comprises a 10µm-size or larger sub-visible particulate count of less than or equal to particles per mL.
17. The apparatus of claim 1, wherein the injection solution contained in the barrel comprises a 25µm-size or larger sub-visible particulate count of less than or equal to 5 particles per mL
18. The apparatus of claim 1, wherein the injection solution contained in the barrel comprises a 50µm-size or larger sub-visible particulate count of less than or equal to 2 particles per mL.
19. The apparatus of claim 1, wherein the injection solution contained in the barrel comprises a 50µm-size or larger sub-visible particulate concentration of less than 150 ppb.
20. The apparatus of claim 1, wherein the injection solution contained in the barrel comprises a 25µm-size or larger sub-visible particulate concentration of less than 150 ppb.
21. The apparatus of claim 1, wherein the injection solution contained in the barrel comprises a 10µm-size or larger sub-visible particulate concentration of less than 150 ppb.
22. The apparatus of claim 1, wherein the injection solution contained in the barrel has a volume of about 200 µL.
23. The apparatus of claim 1, wherein the injection solution contained in the barrel has a volume of about 100 µL.
24. The apparatus of claim 1, wherein the injection solution contained in the barrel has a volume of about 90 µL.
25. The apparatus of claim 1, wherein the injection solution contained in the barrel has a volume of about 50 µL.
26. The apparatus of claim 1, wherein the apparatus comprises a waste space of less than 60 µL.
27. The apparatus of claim 1, wherein the apparatus comprises a waste space of less than 0.1 µL.
28. The apparatus of claim 1, wherein the apparatus comprises a waste space of less than 0.05 µL.
29. The apparatus of claim 1, wherein the apparatus comprises a waste space of less than 0.001 µL.
30. The apparatus of claim 1, wherein the syringe tip cap is plastic.
31 31. The apparatus of claim 1, wherein the syringe tip cap comprises an elastomeric formulation.
32. The apparatus of claim 1, wherein the syringe tip cap comprises an isoprene blend.
33. The apparatus of claim 1, wherein the syringe tip cap comprises a chlorobutyl or a bromobutyl rubber stopper.
34. The apparatus of claim 1, wherein the needle tip shield is rigid.
35. The apparatus of claim 1, wherein the needle tip shield does not contact the cannula.
36. The apparatus of claim 1, wherein the needle tip shield comprises one or more apertures.
37. The apparatus of claim 1, wherein the needle tip shield is permeable to a sterilizing gas or vapor, or plasma.
38. The apparatus of claim 37, wherein the sterilizing gas or vapor is H2O2 or EtO or plasma generated from H2O2.
39. The apparatus of claim 1, wherein the needle tip shield comprises polypropylene or a styrene block thermoplastic elastomer.
40. The apparatus of claim 1, wherein injection solution contained in the barrel comprises a therapeutic agent.
41. The apparatus of claim 1, wherein the therapeutic agent is an anti-VEGF
aptamer.
aptamer.
42. The apparatus of claim 1, wherein the therapeutic agent is pegaptanib sodium.
43. The apparatus of claim 1, wherein injection solution comprises about 0.003 mg to about 3.0 mg of pegaptanib sodium.
44. The apparatus of claim 1, wherein injection solution comprises about 0.3 mg of pegaptanib sodium.
45. The apparatus of claim 1, wherein the syringe comprises more than one barrel.
46. The apparatus of claim 45, wherein the syringe comprises a first barrel having a proximal and a distal end and a second barrel having a proximal and a distal end, each of the first barrel and the second barrel independently comprises a first injection solution and a second injection solution respectively.
47. The apparatus of claim 46, wherein the first barrel and second barrel are set in a tandem arrangement.
48. The apparatus of claim 46, wherein the first barrel and second barrel are set in a side-by-side arrangement.
49. The apparatus of claim 46, wherein the first injection solution comprises pegaptanib sodium and the second injection solution comprises an anti-PDGF aptamer.
50. The apparatus of claim 45, wherein the syringe comprises:
an outer first compartment having a proximal and distal end and a first sealing member;
an inner second compartment, said inner second compartment is filled with a second injection solution, wherein the inner second compartment functions as the plunger for the outer first compartment;
a piercing device at the distal end of the outer first compartment for piercing the first sealing member;
a first injection solution contained in the outer first compartment; and a second injection solution contained in the inner second compartment.
an outer first compartment having a proximal and distal end and a first sealing member;
an inner second compartment, said inner second compartment is filled with a second injection solution, wherein the inner second compartment functions as the plunger for the outer first compartment;
a piercing device at the distal end of the outer first compartment for piercing the first sealing member;
a first injection solution contained in the outer first compartment; and a second injection solution contained in the inner second compartment.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71786505P | 2005-09-16 | 2005-09-16 | |
US60/717,865 | 2005-09-16 | ||
PCT/US2006/036260 WO2007035621A1 (en) | 2005-09-16 | 2006-09-18 | Ophthalmic syringe |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2622573A1 true CA2622573A1 (en) | 2007-03-29 |
Family
ID=37478598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002622573A Abandoned CA2622573A1 (en) | 2005-09-16 | 2006-09-18 | Ophthalmic syringe |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1924309A1 (en) |
JP (1) | JP2009508593A (en) |
CA (1) | CA2622573A1 (en) |
WO (1) | WO2007035621A1 (en) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2319558B1 (en) | 2006-03-14 | 2014-05-21 | University Of Southern California | Mems device for delivery of therapeutic agents |
EP2666510B1 (en) | 2007-12-20 | 2017-10-18 | University Of Southern California | Apparatus for controlled delivery of therapeutic agents |
WO2009132212A2 (en) * | 2008-04-25 | 2009-10-29 | The Regents Of The University Of California | Device to store and inject corneal graft |
US9849238B2 (en) | 2008-05-08 | 2017-12-26 | Minipumps, Llc | Drug-delivery pump with intelligent control |
WO2009137785A2 (en) | 2008-05-08 | 2009-11-12 | Replenish Pumps, Llc | Drug-delivery pumps and methods of manufacture |
JP5719767B2 (en) | 2008-05-08 | 2015-05-20 | ミニパンプス, エルエルシー | Implantable pump and cannula therefor |
US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
US8399006B2 (en) | 2009-01-29 | 2013-03-19 | Forsight Vision4, Inc. | Posterior segment drug delivery |
JP5758388B2 (en) | 2009-08-18 | 2015-08-05 | ミニパンプス, エルエルシー | Electrolyte drug delivery pump with adaptive control |
WO2012013587A1 (en) * | 2010-07-26 | 2012-02-02 | Sanofi-Aventis Deutschland Gmbh | Multiple needle assembly for an injection device |
US9492315B2 (en) | 2010-08-05 | 2016-11-15 | Forsight Vision4, Inc. | Implantable therapeutic device |
JP6111194B2 (en) | 2010-08-05 | 2017-04-05 | フォーサイト・ビジョン フォー・インコーポレーテッド | Combination drug delivery method and apparatus |
US9033911B2 (en) | 2010-08-05 | 2015-05-19 | Forsight Vision4, Inc. | Injector apparatus and method for drug delivery |
US20140031769A1 (en) | 2010-11-19 | 2014-01-30 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
US10398592B2 (en) | 2011-06-28 | 2019-09-03 | Forsight Vision4, Inc. | Diagnostic methods and apparatus |
EP2548594B1 (en) * | 2011-07-22 | 2023-07-12 | Piramal Critical Care Inc. | Intrathecal baclofen pharmaceutical dosage forms and related delivery system |
EP2739252A4 (en) | 2011-08-05 | 2015-08-12 | Forsight Vision4 Inc | Small molecule delivery with implantable therapeutic device |
PT2755600T (en) | 2011-09-16 | 2021-04-19 | Forsight Vision4 Inc | Fluid exchange apparatus and methods |
EP2578190A1 (en) * | 2011-10-07 | 2013-04-10 | Sanofi-Aventis Deutschland GmbH | Intraocular injection device |
WO2013116061A1 (en) | 2012-02-03 | 2013-08-08 | Forsight Vision4, Inc. | Insertion and removal methods and apparatus for therapeutic devices |
BR112014029795B1 (en) * | 2012-06-01 | 2021-09-21 | Novartis Ag | OPTHALMIC SYRINGE, PRE-FILLED, TERMINALLY STERILIZED AND SYRINGE PACKAGING |
AU2013100360B4 (en) * | 2012-07-03 | 2013-05-16 | Novartis Ag | Device |
JOP20200175A1 (en) * | 2012-07-03 | 2017-06-16 | Novartis Ag | Syringe |
AU2012101677B4 (en) * | 2012-07-03 | 2012-12-20 | Novartis Ag | Device |
AU2013100070B4 (en) * | 2012-07-03 | 2013-04-04 | Novartis Ag | Use of device |
EP2968113B8 (en) | 2013-03-14 | 2020-10-28 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
ES2972168T3 (en) | 2013-03-28 | 2024-06-11 | Forsight Vision4 Inc | Ophthalmic implant for administration of therapeutic substances |
EP3628373A1 (en) | 2013-07-12 | 2020-04-01 | IVERIC bio, Inc. | Methods for treating or preventing opthalmological conditions |
KR200479125Y1 (en) * | 2014-07-11 | 2015-12-21 | 류승호 | Double Needle type Syringe |
EP3060131B1 (en) * | 2013-10-21 | 2019-12-11 | Accuro Technologies Inc. | Double barrel syringe and method to use same for placement confirmation and joint space injection |
JPWO2016006342A1 (en) | 2014-07-08 | 2017-04-27 | テルモ株式会社 | Needle |
US10258503B2 (en) | 2014-07-15 | 2019-04-16 | Forsight Vision4, Inc. | Ocular implant delivery device and method |
EP3191161B1 (en) * | 2014-07-28 | 2020-01-15 | Medical Instrument Development Laboratories, Inc. | Reinforcing slider for surgical hand tool |
MY182793A (en) | 2014-08-08 | 2021-02-05 | Forsight Vision4 Inc | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
CA2967330A1 (en) | 2014-11-10 | 2016-05-19 | Forsight Vision4, Inc. | Expandable drug delivery devices and methods of use |
IL295010A (en) | 2015-03-10 | 2022-09-01 | Regeneron Pharma | Aseptic piercing system and method |
MX2018006234A (en) | 2015-11-20 | 2018-08-14 | Forsight Vision4 Inc | Porous structures for extended release drug delivery devices. |
HRP20231379T1 (en) | 2015-12-03 | 2024-02-16 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf |
EP3439591B1 (en) | 2016-04-05 | 2020-09-23 | ForSight Vision4, Inc. | Implantable ocular drug delivery devices |
EP3445426B1 (en) | 2016-04-22 | 2021-01-13 | Elcam Medical ACS Ltd. | Single slider double barrel syringe for medical diagnostics, therapeutic use, and placement confirmation and joint space injection |
IL311121A (en) | 2017-03-27 | 2024-04-01 | Regeneron Pharma | Sterilisation method |
AU2018260992B9 (en) | 2017-05-05 | 2024-02-15 | Regeneron Pharmaceuticals, Inc. | Auto-injector |
BR112020010053A2 (en) | 2017-11-21 | 2020-11-03 | Forsight Vision4, Inc. | fluid change device for expandable door release system and methods of using it |
ES2965405T3 (en) | 2017-12-13 | 2024-04-15 | Regeneron Pharma | Devices and procedures for precision dosing administration |
US11519020B2 (en) | 2018-05-25 | 2022-12-06 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
JP2022535558A (en) | 2019-06-05 | 2022-08-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Device for precise dose delivery |
US20230080971A1 (en) * | 2021-09-08 | 2023-03-16 | Regeneron Pharmaceuticals, Inc. | Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation |
USD1007676S1 (en) | 2021-11-16 | 2023-12-12 | Regeneron Pharmaceuticals, Inc. | Wearable autoinjector |
KR102617251B1 (en) | 2022-01-14 | 2023-12-28 | 건양대학교산학협력단 | Syringe |
USD1033637S1 (en) | 2022-01-24 | 2024-07-02 | Forsight Vision4, Inc. | Fluid exchange device |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5792099A (en) * | 1995-02-14 | 1998-08-11 | Decamp; Dennis | Syringe and cannula for insertion of viscoelastic material into an eye and method of using same |
US6629963B2 (en) * | 1996-06-20 | 2003-10-07 | Becton, Dickinson And Company | Syringe and needle shield assembly and method of sterilizing such assembly |
JP2002095743A (en) * | 2000-09-22 | 2002-04-02 | Terumo Corp | Liquid pouring implement |
US20030120201A1 (en) * | 2001-12-21 | 2003-06-26 | Abergel R. Patrick | Methods and devices for sclerotherapy |
GB0208627D0 (en) * | 2002-04-16 | 2002-05-22 | Imprint Pharm Ltd | Needle |
US20060167435A1 (en) * | 2003-02-18 | 2006-07-27 | Adamis Anthony P | Transscleral drug delivery device and related methods |
JP2005110735A (en) * | 2003-10-03 | 2005-04-28 | Keizo Tanii | Tandem type 2-layered syringe preparation for filling liquid chemical |
US20050148947A1 (en) * | 2003-12-30 | 2005-07-07 | Advanced Medical Optics, Inc. | Cannula locking device |
-
2006
- 2006-09-18 WO PCT/US2006/036260 patent/WO2007035621A1/en active Application Filing
- 2006-09-18 CA CA002622573A patent/CA2622573A1/en not_active Abandoned
- 2006-09-18 EP EP06803774A patent/EP1924309A1/en not_active Withdrawn
- 2006-09-18 JP JP2008531405A patent/JP2009508593A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP1924309A1 (en) | 2008-05-28 |
WO2007035621A1 (en) | 2007-03-29 |
JP2009508593A (en) | 2009-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2622573A1 (en) | Ophthalmic syringe | |
KR102511477B1 (en) | Methods and devices for treating posterior ocular disorders | |
CA2498489C (en) | Method for subretinal administration of therapeutics including steroids;method for localizing pharmacodynamic action at the choroid and the retina; and related methods for treatment and/or prevention of retinal diseases | |
KR102467714B1 (en) | Methods and devices for the treatment of ocular disease in human subjects | |
JP2019501200A (en) | Methods and devices for treating posterior ocular disorders with aflibercept and other biologics | |
EP2124857B1 (en) | Apparatus for intra-ocular injection | |
EP2578191A1 (en) | Apparatus for intraocular injection | |
Kumar et al. | Recent challenges and advances in ophthalmic drug delivery system | |
JP7489684B2 (en) | Antibiotic solutions and injection methods for preventing eye infections | |
Augustin et al. | Suprachoroidal drug delivery–a new approach for the treatment of severe macular diseases | |
RU2661621C2 (en) | Method of prolongation and enhancement of the therapeutic effect of the action of angiogenesis inhibitors in the treatment of neovascular forms of macular degenerations | |
RU2394535C2 (en) | Method of introducing medications into dub-tenon's space in patients with operated glaucoma | |
Marashi | Effect of Intravitreal Ziv-Aflibercept on Choroidal Neovascularization Membrane Secondary to Post Traumatic Choroidal Rupture | |
Kolesnik et al. | Experimental study to investigate the safety of new intraocular bio-degradable implant for drug delivery to the posterior segment of an eye AA Temnov, Yu. A. Belyy 2, SV Novikov 3, AV Shatskikh 4 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |
Effective date: 20130918 |